0001493152-20-015327.txt : 20200812 0001493152-20-015327.hdr.sgml : 20200812 20200812152101 ACCESSION NUMBER: 0001493152-20-015327 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20200630 FILED AS OF DATE: 20200812 DATE AS OF CHANGE: 20200812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PROVECTUS BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000315545 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900031917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36457 FILM NUMBER: 201095277 BUSINESS ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 BUSINESS PHONE: 865-769-4011 MAIL ADDRESS: STREET 1: 10025 INVESTMENT DRIVE STREET 2: SUITE 250 CITY: KNOXVILLE STATE: TN ZIP: 37932 FORMER COMPANY: FORMER CONFORMED NAME: PROVECTUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20020417 FORMER COMPANY: FORMER CONFORMED NAME: ZAMAGE DIGITAL IMAGING INC DATE OF NAME CHANGE: 20011126 FORMER COMPANY: FORMER CONFORMED NAME: SPM GROUP INC DATE OF NAME CHANGE: 19920703 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

[X]	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2020

[ ]	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-36457

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware		90-0031917
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

10025 Investment Drive, Suite 250 Knoxville, Tennessee		37932
(Address of principal executive offices)		(Zip Code)

866-594-5999

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		N/A		N/A

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	[ ]	Accelerated filer	[ ]

Non-accelerated filer	[X]	Smaller reporting company	[X]

		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of August 11, 2020, was 394,362,475.

TABLE OF CONTENTS

	Page
PART I - FINANCIAL INFORMATION

Cautionary Note Regarding Forward-Looking Statements	1
Item 1. Financial Statements (unaudited)	2
Condensed Consolidated Balance Sheets	2
Condensed Consolidated Statements of Operations	3
Condensed Consolidated Statements of Comprehensive Loss	4
Condensed Consolidated Statements of Changes in Stockholders’ Deficiency	5
Condensed Consolidated Statements of Cash Flows	6
Notes to Condensed Consolidated Financial Statements	7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3. Quantitative and Qualitative Disclosures About Market Risk	22
Item 4. Controls and Procedures	22

PART II - OTHER INFORMATION

Item 1. Legal Proceedings	23
Item 1A. Risk Factors	23
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	23
Item 3. Defaults Upon Senior Securities	24
Item 4. Mine Safety Disclosures	24
Item 5. Other Information	24
Item 6. Exhibits	24

SIGNATURES	25

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains “forward-looking statements” as defined under U.S. federal securities laws. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations. These statements also express management’s current views of future performance, results, and trends and may be identified by their use of terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “may,” “plan,” “predict,” “project,” “should,” “strategy,” “will,” and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements. Readers should not place undue reliance on forward-looking statements. Such statements are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no obligation to update such statements after this date, unless otherwise required by law.

Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements include those discussed in our filings with the U.S. Securities and Exchange Commission (the “SEC”) (including those described in Item 1A of Part I of our Annual Report on Form 10-K for the year ended December 31, 2019 and Item 1A of Part II of this Quarterly Report on Form 10-Q for the quarter ended June 30, 2020), and:

	●	Our potential profits from the sales of investigational drug products PV-10^®, PH-10^®, and/or any other halogenated xanthene-based drug products (if and when approved); and licensing, milestone, royalty, and/or other payments related to these investigational drug products and/or the Company’s liquidation, dissolution or winding up, or any sale, lease, conveyance, or other disposition of any intellectual property relating to halogenated xanthene-based investigational drug products and/or drug substances,

	●	Our ability to raise additional capital, including but not limited to our ability to close on additional tranches of the 2020 Financing pursuant to the 2020 Term Sheet that our Board approved effective as of December 31, 2019, and

	●	The widespread outbreak of an illness or communicable/infectious disease, such as severe acute respiratory syndrome coronavirus 2, and/or a public health crisis, could disrupt our business and adversely affect our operations and financial condition.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

	June 30, 2020			December 31, 2019
	(Unaudited)
Assets

Current Assets:
Cash and cash equivalents	$	1,483,214		$	590,706
Short-term receivables - legal fees, settlement and other, net		3,777			55,058
Prepaid expenses		142,659			350,249

Total Current Assets		1,629,650			996,013

Equipment and furnishings, less accumulated depreciation of $71,676 and $64,630, respectively		51,338			58,384
Operating lease right-of-use asset		157,599			194,400
Patents, net of accumulated amortization of $11,715,455 and $11,487,338, respectively		-			228,107

Total Assets	$	1,838,587		$	1,476,904

Liabilities and Stockholders’ Deficiency

Current Liabilities:
Accounts payable - trade	$	1,457,729		$	1,125,890
Other accrued expenses		1,376,008			1,255,266
Current portion of accrued interest		2,114,852			65,333
Current portion of accrued interest - related parties		1,494,357			-
Current portion of note payable		23,438			-
Current portion of convertible notes payable		15,872,000			500,000
Current portion of convertible notes payable - related parties		6,770,000			-
Current portion of operating lease liability		81,149			76,423

Total Current Liabilities		29,189,533			3,022,912

Accrued interest, non-current portion		-			1,501,864
Accrued interest, non-current portion - related parties		-			1,226,582
Note payable, non-current portion		39,062			-
Convertible notes payable, non-current portion		-			12,997,000
Convertible notes payable, non-current portion - related parties		-			6,670,000
Operating lease liability, non-current portion		86,974			130,658

Total Liabilities		29,315,569			25,549,016

Commitments and contingencies (Note 9)

Stockholders’ Deficiency:
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at June 30, 2020 and December 31, 2019; aggregate liquidation preference of $3,500 at June 30, 2020 and December 31, 2019		-			-
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 390,714,475 and 389,889,475 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively		390,714			389,889
Additional paid-in capital		209,421,800			209,378,835
Accumulated other comprehensive loss		(30,802	)		(24,008	)
Accumulated deficit		(237,258,694	)		(233,816,828	)

Total Stockholders’ Deficiency		(27,476,982	)		(24,072,112	)

Total Liabilities and Stockholders’ Deficiency	$	1,838,587		$	1,476,904

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2020			2019			2020			2019

Operating Expenses:
Research and development	$	696,454		$	1,208,324		$	1,605,900		$	2,245,655
General and administrative		514,394			631,063			1,053,188			1,390,316
Total Operating Expenses		1,210,848			1,839,387			2,659,088			3,635,971

Total Operating Loss		(1,210,848	)		(1,839,387	)		(2,659,088	)		(3,635,971	)
Other Income/(Expense):
EIDL grant		3,000			-			3,000			-
Gain on settlement of lawsuits		-			-			-			675,000
Research and development tax credit		113			(1,131	)		26,364			82,941
Investment and interest income		3,334			19,650			3,413			21,905
Interest expense		(410,404	)		(356,451	)		(815,555	)		(691,024	)
Total Other Income/(Expense)		(403,957	)		(337,932	)		(782,778	)		88,822

Net Loss	$	(1,614,805	)	$	(2,177,319	)	$	(3,441,866	)	$	(3,547,149	)

Basic and Diluted Loss Per Common Share	$	(0.00	)	$	(0.01	)	$	(0.01	)	$	(0.01	)

Weighted Average Number of Common Shares Outstanding - Basic and Diluted		390,714,200			384,773,639			390,635,608			384,769,219

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

(Unaudited)

	For the Three Months Ended						For the Six Months Ended
	June 30,						June 30,
	2020			2019			2020			2019

Net Loss	$	(1,614,805	)	$	(2,177,319	)	$	(3,441,866	)	$	(3,547,149	)
Other Comprehensive Income (Loss):
Foreign currency translation adjustments		2,233			(2,496	)		(30,802	)		(24,859	)
Total Comprehensive Loss	$	(1,612,572	)	$	(2,179,815	)	$	(3,472,668	)	$	(3,572,008	)

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ DEFICIENCY

(Unaudited)

FOR THE SIX MONTHS ENDED JUNE 30, 2020

											Accumulated
	Preferred Stock								Additional		Other
	Series B				Common Stock				Paid-In		Comprehensive			Accumulated
	Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total

Balance at January 1, 2020		100	$	-		389,889,475	$	389,889	$	209,378,835	$	(24,008	)	$	(233,816,828	)	$	(24,072,112	)

Common stock issued upon exercise of warrants		-		-		800,000		800		41,840		-			-			42,640
Comprehensive loss:								-
Net loss		-		-		-		-		-		-			(1,827,061	)		(1,827,061	)
Other comprehensive loss		-		-		-		-		-		(9,027	)		-			(9,027	)

Balance at March 31, 2020		100	$	-		390,689,475	$	390,689	$	209,420,675	$	(33,035	)	$	(235,643,889	)	$	(25,865,560	)

Common stock issued for services		-		-		25,000		25		1,125		-			-			1,150
Warrants issued for services		-		-		-		-		-		-			-			-
Comprehensive loss:
Net loss		-		-		-		-		-		-			(1,614,805	)		(1,614,805	)
Other comprehensive income		-		-		-		-		-		2,233			-			2,233

Balance at June 30, 2020		100	$	-		390,714,475	$	390,714	$	209,421,800	$	(30,802	)	$	(237,258,694	)	$	(27,476,982	)

FOR THE SIX MONTHS ENDED JUNE 30, 2019

											Accumulated
	Preferred Stock								Additional		Other
	Series B				Common Stock				Paid-In		Comprehensive			Accumulated
	Shares		Amount		Shares		Amount		Capital		Loss			Deficit			Total

Balance at January 1, 2019		100	$	-		384,614,528	$	384,615	$	209,092,187	$	-		$	(226,894,291	)	$	(17,417,489	)

Common stock issued upon exercise of warrants		-		-		100,000		100		5,230		-			-			5,330
Comprehensive loss:								-
Net loss		-		-		-		-		-		-			(1,369,830	)		(1,369,830	)
Other comprehensive loss		-		-		-		-		-		(22,363	)		-			(22,363	)

Balance at March 31, 2019		100	$	-		384,714,528	$	384,715	$	209,097,417	$	(22,363	)	$	(228,264,121	)	$	(18,804,352	)

Common stock issued for services		-		-		191,590		191		8,771		-			-			8,962
Warrants issued for services		-		-		-		-		10,113		-			-			10,113
Comprehensive loss:
Net loss		-		-		-		-		-		-			(2,177,319	)		(2,177,319	)
Other comprehensive loss		-		-		-		-		-		(2,496	)		-			(2,496	)

Balance at June 30, 2019		100	$	-		384,906,118	$	384,906	$	209,116,301	$	(24,859	)	$	(230,441,440	)	$	(20,965,092	)

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

	For the Six Months Ended
	June 30,
	2020			2019

Cash Flows From Operating Activities:
Net loss	$	(3,441,866	)	$	(3,547,149	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		1,150			19,075
Noncash lease expense		36,801			-
Depreciation		7,046			42,622
Amortization of patents		228,107			335,560
Changes in operating assets and liabilities
Short term receivables		47,653			49,863
Prepaid expenses		207,590			127,794
Accounts payable - trade		332,134			(1,757,954	)
Other accrued expenses		120,817			481,936
Operating lease liability		(38,958	)		-
Accrued interest expense		815,430			691,024

Net Cash Used In Operating Activities		(1,684,096	)		(3,557,229	)

Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable		2,375,000			4,825,000
Proceeds from issuance of convertible notes payable - related parties		100,000			25,000
Proceeds from note payable		62,500			-
Proceeds from exercise of warrants		42,640			5,330
Net Cash Provided By Financing Activities		2,580,140			4,855,330

Effect of Exchange Rate Changes on Cash		(3,536	)		(24,859	)

Net Increase In Cash and Cash Equivalents		892,508			1,273,242

Cash and Cash Equivalents, Beginning of Period		590,706			50,986

Cash and Cash Equivalents, End of Period	$	1,483,214		$	1,324,228

Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest	$	-		$	-
Income taxes	$	-		$	-

Non-cash investing and financing activities:
Offset of related party receivable and payable	$	-		$	252,750

See accompanying notes to condensed consolidated financial statements.

PROVECTUS BIOPHARMACEUTICALS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

1. Business Organization, Nature of Operations and Basis of Presentation

Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company that is developing immunotherapy medicines based on an entire, wholly-owned family of small molecules called halogenated xanthenes. The Company’s proprietary lead molecule is current Good Manufacturing Practice (“cGMP”) rose bengal disodium (“RBD”).

	●	Oncology: PV-10, an investigational autolytic cancer immunotherapy administered by intralesional (“IL”) injection and formulation of cGMP RBD, is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal (“GI”) tumors (including hepatocellular carcinoma (“HCC”), colorectal cancer metastatic to the liver (“mCRC”), neuroendocrine tumors (“NET”) metastatic to the liver (“mNET”), and uveal melanoma metastatic to the liver (“mUM”), among others). Orphan drug designation status has been granted to IL PV-10 by the U.S. Food and Drug Administration (the “FDA”) for metastatic melanoma in 2006, HCC in 2011, and ocular melanoma (including uveal melanoma) in 2019.

	●	Pediatric Oncology: IL PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). Orphan drug designation status has been granted to IL PV-10 by the FDA for neuroblastoma in 2018.

	●	Hematology: A new systemically-administered formulation of cGMP RBD is undergoing preclinical study for pediatric blood cancers (including leukemia).

	●	Virology: A new systemically-administered formulation of cGMP RBD is undergoing preclinical study for the novel strain of coronavirus (“CoV”), severe acute respiratory syndrome (“SARS”) CoV 2 (“SARS-CoV-2”).

	●	Dermatology: PH-10, an investigational immuno-dermatology agent administered as a topical (“top.”) gel and formulation of cGMP RBD, is undergoing clinical study for inflammatory dermatoses (including psoriasis and atopic dermatitis).

To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2019 filed with the SEC on March 5, 2020. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.

SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at June 30, 2020.

The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. A prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

2. Liquidity and Going Concern

The Company’s cash and cash equivalents were $1,483,214 at June 30, 2020. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop IL PV-10, top. PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital.

During the six months ended June 30, 2020, the Company received a loan of $62,500 under the Paycheck Protection Program (“PPP”) (see Note 4) and received a grant of $3,000 from the Economic Injury Disaster Loan (“EIDL”) under the CARES Act. The grant was recognized as other income during the three and six months ended June 30, 2020.

Subsequent to June 30, 2020, the Company received an aggregate $194,438 in connection with a warrant exercise. The Company also received an aggregate $450,000 in connection with the 2020 Financing. See Note 10 – Subsequent Events.

The Company plans to access capital resources through possible public or private equity offerings, including the 2020 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, IL PV-10 and top. PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2020 Financing or otherwise, it will not be able to pay its obligations as they become due.

The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure you that it will be successful in developing further, co-developing, licensing, and/or commercializing IL PV-10, top. PH-10, and/or any other halogenated xanthene-based drug products of the Company, or entering into any commercial financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2020 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2020 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot assure you that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

3. Critical Accounting Policies

Since the date the Company’s December 31, 2019 consolidated financial statements were issued in its 2019 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.

Recently Issued Accounting Standards

In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its condensed consolidated financial statements and related disclosures.

The CARES Act

On March 27, 2020, President Trump signed the CARES Act into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. Under ASC 740 of GAAP, the effects of new legislation are recognized upon enactment. Accordingly, the CARES Act is effective beginning in the quarter ended March 31, 2020. The adoption of the CARES Act provisions did not have a material impact on the Company’s condensed consolidated financial statements.

4. Convertible Notes Payable

2020 Financing

On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $20,000,000 (the “2020 Financing”). The 2020 Financing will be in the form of secured convertible loans (“Loans”) from investors that will be evidenced by convertible promissory notes (the “2020 Notes”). Subject to the terms and conditions of the 2020 Term Sheet, the Company will use its best efforts to arrange for the 2020 Financing, which amounts will be obtained in several tranches. The proceeds from the 2020 Financing will be used to fund the Company’s clinical development program, as currently constituted and envisioned, and to fund the Company’s general and administrative expenses.

Since the 2020 Financing was launched and through June 30, 2020, the Company had received aggregate Loans of $2,575,000.

The Series D Preferred Stock

As of June 30, 2020, and through the date of filing, the Series D Preferred Stock had not been designated by the Board. Per the terms of the notes issued in connection with the 2017 and 2020 Financings, if the Company has not designated the Series D Preferred Stock or if an insufficient number of Series D Preferred shares exist upon a conversion by a note holder, then the outstanding loans will continue to accrue interest at a rate of 8% per annum until which time the Company has designated a sufficient number of Series D Preferred shares. As a result, the Company did not analyze the notes for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the notes were not convertible as of their respective dates of issuance or as of June 30, 2020.

Convertible Notes Payable – Related Parties

During the six months ended June 30, 2020, the Company entered into additional related party 2020 Notes in the aggregate principal amount of $100,000. As of June 30, 2020, the Company had borrowed $100,000 under these notes.

Convertible Notes Payable – Non-Related Parties

During the six months ended June 30, 2020, the Company entered into additional non-related party 2020 Notes in the aggregate principal amount of $2,375,000. As of June 30, 2020, the Company had borrowed $2,475,000 under these notes.

Notes Payable

On April 20, 2020, the Company received a $62,500 loan under the CARES Act PPP (the “PPP Loan”). The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. The loan principal and accrued interest are forgivable, as long as the borrower uses loan proceeds for eligible uses during a specified period following disbursement, such as payroll, benefits, rent, and utilities, and maintains specified headcount and payroll thresholds. If any portion of a PPP Loan is not forgiven, the unforgiven portion is payable over two years at an interest rate of 1%, with a deferral of payments for the first seven months. The Company intends to use PPP Loan proceeds in a manner that it believes presently qualifies for full forgiveness. We cannot provide assurance that the PPP Loan will be forgiven in full As of June 30, 2020, the Company had not applied for forgiveness of the PPP Loan. Once an amount is forgiven under the PPP Loan, the Company intends to recognize a gain on forgiveness of note payable in the period in which it obtained forgiveness.

5. Related Party Transactions

During the three and six months ended June 30, 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $11,200 and $63,600, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of June 30, 2020 were $37,500.

During the three and six months ended June 30, 2019, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $61,200 and $171,200, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of June 30, 2019 were $37,500. Mr. Horowitz serves as both COO and a Director.

See Note 4 and Note 6 for details of other related party transactions.

6. Receivables

The following table summarizes the receivables at June 30, 2020 and December 31, 2019:

	June 30, 2020
	Tax Credit		Legal Fees			Settlement			Total

Provectus Australia Tax Credit	$	3,777	$	-		$	-		$	3,777
Gross receivable		-		455,500			1,649,043			2,104,543
Reserve for uncollectibility		-		(455,500	)		(1,649,043	)		(2,104,543	)
Net receivable	$	3,777	$	-		$	-		$	3,777

	December 31, 2019
	Tax Credit		Legal Fees			Settlement			Total

Provectus Australia Tax Credit	$	55,058	$	-		$	-		$	55,058
Gross receivable		-		455,500			1,649,043			2,104,543
Reserve for uncollectibility		-		(455,500	)		(1,649,043	)		(2,104,543	)
Net receivable	$	55,058	$	-		$	-		$	55,058

7. Stockholders’ Deficiency

Common Stock

During the six months ended June 30, 2020, warrant holders exercised warrants to purchase an aggregate of 800,000 shares of common stock at an exercise price of $0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $42,640 and issued 800,000 shares of common stock to the holders. Subsequent to June 30, 2020, the Company received an aggregate $194,438 in connection with a warrant exercise. See Note 10 – Subsequent Events.

During the six months ended June 30, 2020, the Company issued an aggregate of 25,000 shares of immediately vested restricted common stock to a consultant with an issuance date fair value of $1,150, which was recognized immediately.

8. Leases

The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022. Payments range from approximately $7,300 to $7,800 per month.

Total operating lease expense for the three months ended June 30, 2020 was $22,332, of which, $14,888 was included within research and development and $7,444 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the three months ended June 30, 2019 was $22,329, of which, $14,886 was included within research and development and $7,443 was included within general and administrative expenses on the condensed consolidated statement of operations.

Total operating lease expense for the six months ended June 30, 2020 was $43,634, of which, $29,090 was included within research and development and $14,544 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the six months ended June 30, 2019 was $57,134, of which, $38,089 was included within research and development and $19,045 was included within general and administrative expenses on the condensed consolidated statement of operations.

As of June 30, 2020, the Company had no leases that were classified as a financing lease. As of June 30, 2020, the Company did not have additional operating and financing leases that have not yet commenced.

A summary of the Company’s right-of-use assets and liabilities is as follows:

	Six Months Ended June 30, 2020

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases	$	44,882

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	-

Weighted Average Remaining Lease Term
Operating leases		2.0 Years

Weighted Average Discount Rate
Operating leases		8.0	%

Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2020 were as follows:

Years	Amount

2020		45,784
2021		92,471
2022		46,687
Total future minimum lease payments		184,943
Less: amount representing imputed interest		(16,819	)
Total	$	168,123

9. Commitments, Contingencies and Litigation

Culpepper Travel Expenses and Related Collection Efforts

On December 27, 2016, the then-Board of Directors (the “then-Board”) unanimously voted to terminate then-interim Chief Executive Officer, then-Chief Operating Officer, and former Chief Financial Officer, Peter Culpepper (“Culpepper”), effective immediately, from all positions he held with the Company and each of its subsidiaries, “for cause,” in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”), based on the results of the investigation conducted by the Audit Committee of the then-Board regarding improper expense reimbursements to Culpepper.

The Company took the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Stipulated Settlement Agreement and Mutual Release in the Kleba Derivative Lawsuit Settlement (the “Derivative Lawsuit Settlement”) such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,104,543 as of June 30, 2020 and December 31, 2019, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount.

Culpepper disputed that he was terminated “for cause” under the Culpepper Employment Agreement. On June 28, 2017, pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating Culpepper’s claim against the Company for severance and the Company’s claims against Culpepper for improper expense reimbursements and amounts Culpepper owed the Company under the Derivative Lawsuit Settlement. On September 12, 2018, the arbitrator issued his final award in favor of the Company.

On October 4, 2018, the Company filed a petition with the Chancery Court for Davidson County, Tennessee to confirm the arbitration award. On January 23, 2019, the Chancery Court entered an order confirming the arbitrator’s award. On February 20, 2019, Culpepper filed a motion to alter or amend the Chancery Court’s judgment. On March 22, 2019, the Chancery Court upheld the arbitration award in favor of the Company.

On April 16, 2019, Culpepper filed a Notice of Appeal with the Tennessee Court of Appeals regarding the Chancery Court’s judgment. The Company and Culpepper submitted their respective court of appeal briefs on November 12, 2019 and December 3, 2019, respectively. Oral arguments were held on January 7, 2020. On April 14, 2020, the Court of Appeals affirmed the Chancery Court’s judgment and awarded court costs to the Company.

On June 16, 2020, Culpepper filed an application to the Supreme Court of Tennessee for permission to appeal the Court of Appeals’ final decision. On June 30, 2020, the Company filed an answer to the Supreme Court in opposition to Culpepper’s application for permission to appeal. On August 5, 2020, the Supreme Court denied Culpepper’s application.

10. Subsequent Events

Convertible Notes Payable

Subsequent to June 30, 2020, the Company entered into a 2020 Note with a non-related party in the aggregate principal amount of $450,000 in connection with a 2^ndLoan received by the Company for the same amount.

Exercise of Warrants

Subsequent to June 30, 2020, a warrant holder exercised warrants to purchase an aggregate of 3,648,000 shares of common stock at $0.0533 per share. In connection with this exercise, the Company received aggregate cash proceeds of $194,438.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion is intended to assist in the understanding and assessment of significant changes and trends related to our results of operations and our financial condition together with our consolidated subsidiaries. This discussion and analysis should be read in conjunction with the accompanying unaudited financial statements and our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 5, 2020 (“2019 Form 10-K”), which includes additional information about our critical accounting policies and practices and risk factors. Historical results and percentage relationships set forth in the statement of operations, including trends which might appear, are not necessarily indicative of future operations.

Overview

Provectus is a clinical-stage biotechnology company developing immunotherapy medicines based on an entire, wholly-owned family of chemical small molecules called halogenated xanthenes. The Company’s proprietary lead molecule is cGMP RBD. IL PV-10, the first small molecule autolytic immunotherapy and a formulation of cGMP RBD, can induce immunogenic cell death (“ICD”), and is undergoing clinical study for adult solid tumor cancers, such as melanoma and GI tumors (e.g., HCC, mCRC, mNET, mUM), and preclinical study for pediatric solid tumor cancers (e.g., neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, osteosarcoma). Topically-administered PH-10, an immune-modulatory agent and formulation of cGMP RBD, is undergoing clinical study for inflammatory dermatoses (e.g., psoriasis, atopic dermatitis). New systemically-administered formulations of cGMP RBD are being investigated for hematology (e.g., acute myeloid leukemia, acute monocytic leukemia) and virology (e.g., SARS-CoV-2).

The SARS-CoV-2 pandemic has already caused significant disruptions in the financial markets, and may continue to cause such disruptions, which could impact our ability to raise additional funds and may also impact the volatility of our stock price and trading in our stock. Moreover, the pandemic has also significantly impacted economies worldwide, which could result in adverse effects on our business and operations. We cannot be certain what the overall impact of the SARS-CoV-2 pandemic will be on our business. It has the potential to adversely affect our business, financial condition, results of operations, and prospects. We have taken several temporary precautionary measures intended to help ensure the well-being of our employees and contractors and to minimize disruption to our business. We considered the impact of SARS-CoV-2 pandemic on our business and operational assumptions and estimates, and determined there were no material adverse impacts on our results of operations and financial position at June 30, 2020.

Our Science and Technology

Oncology. IL PV-10 drug product is Provectus’ cGMP injectable formulation of the Company’s pharmaceutical-grade (cGMP) RBD (4,5,6,7-tetrachloro-2’,4’,5’,7’-tetraiodofluorescein disodium salt) drug substance. RBD selectively accumulates in the lysosomes of cancer cells. Cancer cells, particularly advanced cancer cells, are very dependent on effective lysosomal functioning (Piao et al., Ann N Y Acad Sci 2016). Cancer progression and metastasis are associated with lysosomal compartment changes (Nishimura et al., Pathol Oncol Res 1998; Gocheva et al., Genes Dev 2006), which are closely correlated with, among other things, invasive growth, angiogenesis, and drug resistance (Fahrenbacher et al., Cancer Res 2005).

Lysosomes are the central organelles for intracellular degradation of biological macromolecules and organelles. Discovered by Christian de Duve, M.D. in 1955, lysosomes have been linked with a number of biological processes like cell death, inflammasome activation, and immune response. In 1959, Dr. de Duve described lysosomes as “suicide bags,” because their rupture led to cell death and tissue autolysis. Lysosomes have been shown to play a role in each of the primary pathways of cell death, which are apoptosis, autophagy, and necrosis. He was awarded the Nobel Prize in 1974 for discovering and characterizing lysosomes.

Provectus showed that RBD selectively accumulates in the lysosomes of cancer cells and disrupts them, causing the cancer cells to die. RBD has also been shown by Provectus and independent researchers to trigger each major, distinct form of lysosomal cell death; that is, apoptosis, autophagy, and necrosis.

RBD’s lysosomal targeting comprises:

	●	Transiting the plasmalemma (i.e., the cell membrane) of cancer cells. RBD penetrates the cell membrane of cancerous cells which normally protects the cancer cell from its surrounding environment. RBD, however, is excluded from normal cells;

	●	Accumulating in the lysosomes of cancer cells. As noted above, the physicochemical properties of lysosomes trap RBD;

	●	Triggering the release of lysosomal contents. Acute autolysis can occur within 60 minutes. Early preclinical work by Provectus on RBD’s lysosomal targeting showed identical responses in different disease models, such as Hepa1-6 murine hepatocellular carcinoma, HTB-133 human breast carcinoma, and H96Ar human multi-drug resistant small cell lung carcinoma;

	●	Inducing the rapid cell death of cancer cells. Early trypan blue exclusion work by Provectus confirmed cell death within hours; and,

	●	Intracellular pH consistency with the release of acidic lysosomal contents. Early seminaphthorhodafluor-1 (“SNARF-1”) staining work by Provectus confirmed lower intracellular pH upon exposure to RBD.

Hematology. In primary cells and cell lines derived from pediatric leukemia patients, RBD may lead to stimulator of interferon genes (“STING”) dimerization and the release of interferon gamma, indicating a potential immune activation mechanism of RBD. Heat shock proteins, which chaperone misfolded or abnormally-folded proteins, associated with STING dimerization in RBD-treated cells, indicating a mechanism that may lead to enhanced STING activation following RBD-specific treatment.

Virology. The Company’s work in this disease area to identify activity and elucidate mechanism(s) of action is ongoing.

Dermatology. For psoriasis, pathways significantly improved by PH-10 drug product treatment include published psoriasis transcriptomes and cellular responses mediated by IL-17, IL-22, and interferons. Clinical work has shown that more than 500 disease-related genes were down-regulated after four weeks of application and a wide-range of central psoriasis-related genes, including IL-23, IL-17, IL-22, S100A7, IL-19, IL-36, and CXCL1, were normalized (i.e., treated lesional skin had values in the same range as baseline non-lesional skin).

Our Drug Development Strategy

Oncology. The Company’s strategy is to (i) demonstrate the independent action of single-agent IL PV-10; that is, safety and activity in T cell and non-T cell inflamed tumor types, in high and low tumor mutation burden tumor types, and in other tumor type categories, such as gene mutations, (ii) demonstrate the coordinated induction of multiple immune signaling pathways (i.e., functional ICD); Snyder et al., Sci Immunol 2019) by IL PV-10 treatment, (iii) demonstrate the functional T cell response generated by IL PV-10 treatment, and (iv) contrast and compare IL PV-10 treatment (i.e., safety, activity, and induced immune response) with that of immune checkpoint blockade (“CB”) and other drug classes in single-agent and IL PV-10-based combination therapy settings.

This strategy may quicken the advancement of single-agent IL PV-10 along a pathway-to-approval in solid tumor cancer indications where there is high unmet need, limited activity from other therapies, and the opportunity to display the immune response from IL PV-10 treatment, such as mNET (NCT02693067). This strategy may also permit the Company to develop and advance a cancer combination therapy involving one or more CB and/or other drug classes along a pathway-to-approval in a disease indication where there is high unmet need, limited activity from standard of care (“SOC”) treatment, and the opportunity to display how IL PV-10 augments clinical response to existing or emerging SOCs, such as mUM (i.e., combination therapy with an anti-CTLA-4 agent and an anti-PD-1 agent) (NCT00986661).

Hematology. The Company and research collaborators are undertaking preclinical work on a potential, systemically-administered, cGMP RBD leukemia treatment and/or cancer vaccine for pediatric patients.

Virology. The Company and research collaborators are undertaking preclinical work on a potential, systemically-administered, cGMP RBD therapy for SARS-CoV-2.

Dermatology. The Company’s strategy is to (i) demonstrate 12-week single-agent administration proof-of-concept (“POC”) for top. PH-10 that includes (a) a preclinical safety study of extended 12-week administration (compared to, previously, four weeks), (b) a clinical mechanism of action study in atopic dermatitis, which would be a “book-end” trial to the already completed clinical mechanism study in psoriasis, (c) Phase 2 randomized controlled trials of top. PH-10 for the treatment of psoriasis and atopic dermatitis that may potentially utilize SOC comparators, and (d) end-of-Phase 2 meetings with the FDA upon the completion of the abovementioned Phase 2 trials, and (ii) expand POC top. PH-10 treatment to include dermatology combination therapy. Our goal for this POC work is to achieve Phase 3 trial-ready status for top. PH-10 in both psoriasis and atopic dermatitis.

Components of Operating Results

Research and Development Expenses

A large component of our total operating expenses is the Company’s investment in research and development activities, including the clinical development of our product candidates. Research and development expenses represent costs incurred to conduct research and undertake clinical trials to develop our drug product candidates. These expenses consist primarily of:

	●	Costs of conducting clinical trials, including amounts paid to clinical centers, clinical research organizations and consultants, among others;
	●	Salaries and related expenses for personnel, including stock-based compensation expense;
	●	Other outside service costs including cost of contract manufacturing;
	●	The costs of supplies and reagents; and,
	●	Occupancy and depreciation charges.

We expense research and development costs as incurred.

Research and development activities are central to our business model. We expect our research and development expenses to increase in the future as we advance our existing product candidates through clinical trials and pursue their regulatory approval. Undertaking clinical development and pursuing regulatory approval are both costly and time-consuming activities. As a result of known and unknown uncertainties, we are unable to determine the duration and completion costs of our research and development activities, or if, when, and to what extent we will generate revenue from any subsequent commercialization and sale of our drug product candidates.

General and Administrative Expenses

General and administrative expense consists primarily of salaries, stock-based compensation expense and other related costs for personnel in executive, finance, accounting, business development, legal, information technology and corporate communication functions. Other costs include facility costs not otherwise included in research and development expense, insurance, and professional fees for legal, patent and accounting services.

Results of Operations

Comparison of the Three Months Ended June 30, 2020 and June 30, 2019

Overview

Total operating expenses were $1,210,848 for the three months ended June 30, 2020, a decrease of $628,539 or 34.2% compared to the three months ended June 30, 2019. The decrease was driven primarily by our continued transformation and process improvement efforts within the Company and closure of our phase III trial, as well as slower enrollments and treatments in our clinical trials due to the SARS-CoV-2 pandemic. Net loss for the three months ended June 30, 2020 was $1,614,805, a decrease of $562,514 or 25.8% which was primarily attributable to lower expenses incurred as a result of the SARS-CoV-2 pandemic.

	For the Three Months Ended
	June 30,
	2020			2019			Increase/(Decrease)			% Change

Operating Expenses:
Research and development	$	696,454		$	1,208,324		$	(511,870	)		-42.4	%
General and administrative		514,394			631,063			(116,669	)		-18.5	%
Total Operating Expenses		1,210,848			1,839,387			(628,539	)		-34.2	%

Total Operating Loss		(1,210,848	)		(1,839,387	)		628,539			-34.2	%
Other Income/(Expense):
EIDL grant		3,000			-			3,000			0.0	%
Gain on settlement of lawsuits		-			-			-			0.0	%
Research and development tax credit		113			(1,131	)		1,244			0.0	%
Investment and interest income		3,334			19,650			(16,316	)		-83.0	%
Interest expense		(410,404	)		(356,451	)		(53,953	)		15.1	%
Total Other Income/(Expense)		(403,957	)		(337,932	)		(66,025	)		19.5	%

Net Loss	$	(1,614,805	)	$	(2,177,319	)	$	562,514			-25.8	%

Research and Development Expenses

Research and development expenses were $696,454 for the three months ended June 30, 2020, a decrease of $511,870 or 42.4% compared to the three months ended June 30, 2019. The decrease was primarily due to (i) reduced cost on clinical trials and research expenses due to slow enrollments and treatments in clinical trials due to the SARS-CoV-2 pandemic, and (ii) a decrease in amortization of patents due to patents being fully amortized.

The following table summarizes our research and development expenses incurred during the three months ended June 30, 2020 and June 30, 2019:

	For the Three Months Ended
	June 30,
	2020		2019		Increase/(Decrease)			% Change

Operating Expenses:
Research and development:
Clinical trial and research expenses	$	477,384	$	910,591	$	(433,207	)		-47.6	%
Depreciation/amortization		62,489		169,942		(107,453	)		-63.2	%
Insurance		72,685		61,049		11,636			19.1	%
Payroll and taxes		68,282		50,932		17,350			34.1	%
Rent and utilities		15,614		15,811		(197	)		-1.2	%
Total research and development	$	696,454	$	1,208,324	$	(511,870	)		-42.4	%

General and Administrative Expenses

General and administrative expenses were $514,394 for the three months ended June 30, 2020, a decrease of $116,669 or 18.5% compared to the three months ended June 30, 2019. The decrease was primarily due to (i) lower legal fees as we concluded the Company’s lawsuits against former accounting vendors, (ii) a decrease in payroll and related taxes, and (iii) lower professional fees as a result of lower negotiated rates.

The following table summarizes our general and administrative expenses incurred during the three months ended June 30, 2020 and June 30, 2019:

	For the Three Months Ended
	June 30,
	2020		2019		Increase/(Decrease)			% Change

Operating Expenses:
General and administrative:
Depreciation	$	1,362	$	1,362	$	-			0.0	%
Directors fees		96,250		96,250		-			0.0	%
Insurance		53,610		43,446		10,164			23.4	%
Legal and litigation		129,563		153,716		(24,153	)		-15.7	%
Other general and administrative cost		18,766		45,207		(26,441	)		-58.5	%
Payroll and taxes		48,436		75,168		(26,732	)		-35.6	%
Professional fees		158,318		207,265		(48,947	)		-23.6	%
Rent and utilities		8,078		8,648		(570	)		-6.6	%
Foreign currency translation		11		-		11			0.0	%
Total general and administrative	$	514,394	$	631,063	$	(116,669	)		-18.5	%

Other Income/(Expense)

Other income decreased by $66,025 from $337,932 for the three months ended June 30, 2019 to $403,957 for the three months ended June 30, 2020.

Interest expense increased by $53,953 from $356,451 for the three months ended June 30, 2019 to $410,404 for the three months ended June 30, 2020. The increase was due to the increased number of convertible notes payable outstanding relating to the PRH Notes from the 2017 and 2020 Financings.

Comparison of the Six Months Ended June 30, 2020 and June 30, 2019

Overview

Total operating expenses were $2,659,088 for the six months ended June 30, 2020, a decrease of $976,883 or 26.9% compared to the six months ended June 30, 2019. The decrease was driven primarily by our continued transformation and process improvement efforts within the Company, as well as, slower enrollments and treatments in our clinical trials due to the SARS-CoV-2 pandemic. Net loss for the six months ended June 30, 2020 was $3,441,866, a decrease of $102,283 or 2.9% which was primarily attributable to gains recognized in connection with settlements of lawsuits in 2019.

	For the Six Months Ended
	June 30,
	2020			2019			Increase/(Decrease)			% Change

Operating Expenses:
Research and development	$	1,605,900		$	2,245,655		$	(639,755	)		-28.5	%
General and administrative		1,053,188			1,390,316			(337,128	)		-24.2	%
Total Operating Expenses		2,659,088			3,635,971			(976,883	)		-26.9	%

Total Operating Loss		(2,659,088	)		(3,635,971	)		(976,883	)		26.9	%
Other Income/(Expense):
EIDL grant		3,000			-			3,000			0.0	%
Gain on settlement of lawsuits		-			675,000			(675,000	)		-100.0	%
Research and development tax credit		26,364			82,941			(56,577	)		-68.2	%
Investment and interest income		3,413			21,905			(18,492	)		-84.4	%
Interest expense		(815,555	)		(691,024	)		(124,531	)		18.0	%
Total Other Income/(Expense)		(782,778	)		88,822			(874,600	)		-984.7	%

Net Loss	$	(3,441,866	)	$	(3,547,149	)	$	(102,283	)		2.9	%

Research and Development Expenses

Research and development expenses were $1,605,900 for the six months ended June 30, 2020, a decrease of $639,755 or 28.5% compared to the six months ended June 30, 2019. The decrease was primarily due to (i) reduced cost on clinical trials and research expenses with closure of the phase III trial and slower enrollments and treatments in clinical trials due to the SARS-CoV-2 pandemic, (ii) a decrease in payroll and related taxes due to a lower negotiated employment agreement, and (iii) a decrease in amortization of patents due to patents being fully amortized.

The following table summarizes our research and development expenses incurred during the six months ended June 30, 2020 and June 30, 2019:

	For the Six Months Ended
	June 30,
	2020		2019		Increase/(Decrease)			% Change

Operating Expenses:
Research and development:
Clinical trial and research expenses	$	1,061,441	$	1,538,126	$	(476,685	)		-31.0	%
Depreciation/amortization		232,431		339,884		(107,453	)		-31.6	%
Insurance		146,277		127,012		19,265			15.2	%
Payroll and taxes		134,761		200,407		(65,646	)		-32.8	%
Rent and utilities		30,990		40,226		(9,236	)		-23.0	%
Total research and development	$	1,605,900	$	2,245,655	$	(639,755	)		-28.5	%

General and Administrative Expenses

General and administrative expenses were $1,053,188 for the six months ended June 30, 2020, a decrease of $337,128 or 24.2% compared to the six months ended June 30, 2019. The decrease was primarily due to (i) lower legal fees as we concluded the Company’s lawsuits against former accounting vendors, (ii) a decrease in payroll and related taxes, and (iii) lower professional fees as a result of lower negotiated rates.

The following table summarizes our general and administrative expenses incurred during the six months ended June 30, 2020 and June 30, 2019:

	For the Six Months Ended
	June 30,
	2020		2019			Increase/(Decrease)			% Change

Operating Expenses:
General and administrative:
Depreciation	$	2,723	$	2,723		$	-			0.0	%
Directors fees		192,500		192,500			-			0.0	%
Insurance		95,476		91,842			3,634			4.0	%
Legal and litigation		217,625		347,357			(129,732	)		-37.3	%
Other general and administrative cost		35,773		69,679			(33,906	)		-48.7	%
Payroll and taxes		83,922		198,439			(114,517	)		-57.7	%
Professional fees		408,329		467,477			(59,148	)		-12.7	%
Rent and utilities		15,738		21,087			(5,349	)		-25.4	%
Foreign currency translation		1,102		(788	)		1,890			-239.8	%
Total general and administrative	$	1,053,188	$	1,390,316		$	(337,128	)		-24.2	%

Other Income/(Expense)

Other income decreased by $874,600 from $88,822 for the six months ended June 30, 2019 to a loss of $782,778 for the six months ended June 30, 2020 which was primarily attributable to gains recognized in connection with settlements of lawsuits in 2019.

Interest expense increased by $124,531 from $691,024 for the six months ended June 30, 2019 to $815,555 for the six months ended June 30, 2020. The increase was due to the increased number of convertible notes payable outstanding relating to the PRH Notes from the 2017 and 2020 Financings.

Liquidity and Capital Resources

Our cash and cash equivalents were $1,483,214 at June 30, 2020, compared to $590,706 at December 31, 2019. The condensed consolidated financial statements and notes thereto included in this Quarterly Report on Form 10-Q have been prepared on a basis that contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. We have continuing net losses and negative cash flows from operating activities. In addition, we have an accumulated deficit of $237,258,694 as of June 30, 2020. These conditions raise substantial doubt about our ability to continue as a going concern for a period within one year from the date that the financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. Our financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to obtain additional financing as may be required to fund current operations.

During the six months ended June 30, 2020, we received a loan of $62,500 under the Paycheck Protection Program (“PPP”) and received a grant of $3,000 from the Economic Injury Disaster Loan (“EIDL”) under the CARES Act. The grant was recognized as other income during the three and six months ended June 30, 2020.

Management’s plans include selling our equity securities and obtaining other financing to fund our capital requirement and on-going operations, including the 2020 Financing; however, there can be no assurance we will be successful in these efforts. The financial statements do not include any adjustment that might be necessary if we are unable to continue as a going concern. Significant funds will be needed to continue and complete our ongoing and planned clinical trials.

Access to Capital

Management plans to access capital resources through possible public or private equity offerings, including the 2020 Financing, exchange offers, debt financings, corporate collaborations or other means. If we are unable to raise sufficient capital through the 2020 Financing or otherwise, we will not be able to pay our obligations as they become due.

The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, we cannot assure you that management will be successful in implementing the Company’s business plan of developing, licensing, and/or commercializing our prescription drug product candidates. Moreover, even if we are successful in improving our current cash flow position, we nonetheless plan to seek additional funds to meet our current and long-term requirements in 2020 and beyond. We anticipate that these funds will otherwise come from the proceeds of private placement transactions, including the 2020 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While we believe that we have a reasonable basis for our expectation that we will be able to raise additional funds, we cannot assure you that we will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

Critical Accounting Policies

For a description of our critical accounting policies, see Note 3 – Critical Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Recently Issued Accounting Standards

Recently issued accounting standards are included in Note 3 – Critical Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, financings, or other relationships with unconsolidated entities or other persons, also known as special purpose entities (“SPEs”).

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, carried out an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Based on this evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during the fiscal quarter covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

The information required by this item is incorporated by reference from Part I, Item 1. Financial Statements, Notes to Condensed Consolidated Financial Statements, Note 9.

ITEM 1A. RISK FACTORS.

There have been no material changes to the risk factors that were disclosed in the 2019 Form 10-K, other than set forth below.

Our business, financial condition and results of operations may be adversely affected by the severe acute respiratory syndrome (“SARS”)-associated CoV-2 (“SARS-CoV-2”) pandemic or other similar outbreaks of contagious diseases.

Outbreaks of contagious diseases and other adverse public health developments, affecting us and/or the third parties on which we rely, could have a material and adverse effect on our business, financial condition and results of operations. SARS-CoV-2 pandemic, which was reported to have begun in late-2019 and has spread worldwide, has resulted in slower enrollment and treatments in our clinical trials and may affect our ability to initiate and/or complete current and/or or future preclinical studies and/or clinical trials; disrupt our regulatory activities; and/or have other adverse effects on our clinical development. In addition, stay-at-home orders, business closures, travel restrictions, supply chain disruptions and employee or independent contractor illness or quarantines could result in disruptions to our operations, which could adversely impact our results from operations and financial condition. The SARS-CoV-2 pandemic has also caused substantial disruption in capital and financial markets and adversely impacted economies worldwide, any and/or all of which may disrupt our business, negatively impact our ability to raise additional funds, and adversely affect our results of operations and financial condition. Moreover, many risk factors set forth in the 2019 Form 10-K should be interpreted as heightened risks as a result of the impact of the SARS-CoV-2 pandemic. The extent to which the SARS-CoV-2 pandemic may impact our business, financial condition and results of operations will depend on the manner in which this pandemic continues to evolve and future developments in response thereto, which are highly uncertain and cannot be predicted with confidence as of the date of this Form 10-Q.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

2020 Financing

During the three months ended June 30, 2020, the Company did not enter into any additional 2020 Notes with related party investors. As of June 30, 2020, the Company had drawn down the entire $100,000 under 2020 Notes with related party investors.

During the three months ended June 30, 2020, the Company entered into additional 2020 Notes with non-related party accredited investors in the aggregate principal amount of $2,175,000. As of June 30, 2020, the Company had drawn down the entire $2,475,000 under 2020 Notes with non-related party accredited investors.

The Company believes that such transactions were exempt from the registration requirements of the Securities Act of 1933, as amended, (the “Securities Act”), in reliance on Section 4(a)(2) of the Securities Act (or Rule 506 of Regulation D promulgated thereunder) as transactions by an issuer not involving a public offering.

For further details on the terms of the 2017 and 2020 Notes, refer to our Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the SEC on March 5, 2020.

Incentive Compensation to Consultants

During the three months ended June 30, 2020, the Company issued 25,000 shares of common stock to a consultant in connection with the contract entered into on April 1, 2019. The Company believes that such transactions were exempt from the registration requirements of the Securities Act in reliance on Section 4(a)(2) of the Securities Act (or Rule 506 of Regulation D promulgated thereunder) as a transaction by an issuer not involving a public offering.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. Mine Safety Disclosures.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit No.		Description

31.1**		Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

31.2**		Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) (Section 302 Certification).

32***		Certification of Principal Executive Officer and Chief Financial Officer Pursuant to 18 U.S.C. Section 1350 (Section 906 Certification).

101**		Interactive Data Files.

** Filed herewith.

*** Furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	PROVECTUS BIOPHARMACEUTICALS, INC.

August 12, 2020	By:	/s/ Bruce Horowitz
		Bruce Horowitz
		Chief Operating Officer (Principal Executive Officer)

	By:	/s/ Heather Raines
		Heather Raines, CPA
		Chief Financial Officer (Principal Financial Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION

I, Bruce Horowitz, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Biopharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2020	By:	/s/ Bruce Horowitz
		Bruce Horowitz
		Chief Operating Officer (Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION

I, Heather Raines, CPA, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Provectus Biopharmaceuticals, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 12, 2020	By:	/s/ Heather Raines
		Heather Raines, CPA
		Chief Financial Officer (Principal Financial Officer)

EX-32 4 ex32.htm

Exhibit 32

CERTIFICATION PURSUANT TO RULE 13a-14(b) UNDER

THE SECURITIES EXCHANGE ACT OF 1934 AND

SECTION 1350 OF CHAPTER 63 OF TITLE 18 OF THE UNITED STATES CODE

Each of the undersigned, Bruce Horowitz, the Chief Operating Officer (principal executive officer) of Provectus Biopharmaceuticals, Inc. (the “Company”), and Heather Raines, CPA, the Chief Financial Officer (principal financial officer) of the Company, certifies, pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code, that (1) this Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act, and (2) the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of the Company.

This Certification is signed on August 12, 2020.

	By:	/s/ Bruce Horowitz
		Bruce Horowitz
		Chief Operating Officer (Principal Executive Officer)

	By:	/s/ Heather Raines
		Heather Raines, CPA
		Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 pvct-20200630.xml XBRL INSTANCE FILE 0000315545 2018-12-31 0000315545 us-gaap:CommonStockMember 2018-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000315545 us-gaap:RetainedEarningsMember 2018-12-31 0000315545 us-gaap:SeriesBPreferredStockMember 2018-12-31 0000315545 2020-01-01 2020-06-30 0000315545 2019-12-31 0000315545 PVCT:SeriesBConvertiblePreferredStockMember 2019-12-31 0000315545 us-gaap:SeriesBPreferredStockMember 2019-12-31 0000315545 us-gaap:CommonStockMember 2019-12-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000315545 us-gaap:RetainedEarningsMember 2019-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000315545 PVCT:KnoxvilleTennesseeMember 2020-06-30 0000315545 PVCT:KnoxvilleTennesseeMember 2020-01-01 2020-06-30 0000315545 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000315545 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 0000315545 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000315545 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-06-30 0000315545 PVCT:KnoxvilleTennesseeMember srt:MinimumMember 2020-01-01 2020-06-30 0000315545 PVCT:KnoxvilleTennesseeMember srt:MaximumMember 2020-01-01 2020-06-30 0000315545 2019-01-01 2019-06-30 0000315545 PVCT:LegalFeesMember 2019-12-31 0000315545 PVCT:SettlementMember 2019-12-31 0000315545 us-gaap:SeriesBPreferredStockMember 2019-04-01 2019-06-30 0000315545 us-gaap:SeriesBPreferredStockMember 2019-06-30 0000315545 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000315545 us-gaap:CommonStockMember 2019-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000315545 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000315545 us-gaap:RetainedEarningsMember 2019-06-30 0000315545 2019-04-01 2019-06-30 0000315545 2019-06-30 0000315545 2020-08-11 0000315545 PVCT:TwoThousandAndTwentyFinancingMember srt:MaximumMember 2019-12-31 0000315545 PVCT:TwoThousandAndTwentyNotesMember PVCT:RelatedPartyMember 2020-06-30 0000315545 PVCT:MrBruceHorowitzMember 2020-01-01 2020-06-30 0000315545 PVCT:MrBruceHorowitzMember 2019-01-01 2019-06-30 0000315545 us-gaap:AustralianTaxationOfficeMember 2019-12-31 0000315545 PVCT:CulpepperEmploymentAgreementMember PVCT:PeterCulpepperMember 2019-12-31 0000315545 PVCT:TwoThousandSeventeenAndTwentyTwentyFinancingsMember 2020-06-30 0000315545 PVCT:TwoThousandAndTwentyNotesMember PVCT:NonRelatedPartyMember 2020-06-30 0000315545 2020-06-30 0000315545 PVCT:SeriesBConvertiblePreferredStockMember 2020-06-30 0000315545 us-gaap:SeriesBPreferredStockMember 2020-06-30 0000315545 us-gaap:CommonStockMember 2020-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000315545 us-gaap:RetainedEarningsMember 2020-06-30 0000315545 PVCT:TwoThousandAndTwentyFinancingMember 2020-01-01 2020-06-30 0000315545 us-gaap:AustralianTaxationOfficeMember 2020-06-30 0000315545 PVCT:WarrantHoldersMember 2020-06-30 0000315545 PVCT:WarrantHoldersMember 2020-01-01 2020-06-30 0000315545 PVCT:CulpepperEmploymentAgreementMember PVCT:PeterCulpepperMember 2020-01-01 2020-06-30 0000315545 PVCT:CulpepperEmploymentAgreementMember PVCT:PeterCulpepperMember 2020-06-30 0000315545 PVCT:PaycheckProtectionProgramMember PVCT:TheCARESActMember 2020-04-20 0000315545 PVCT:LegalFeesMember 2020-06-30 0000315545 PVCT:SettlementMember 2020-06-30 0000315545 2020-04-01 2020-06-30 0000315545 us-gaap:SeriesBPreferredStockMember 2020-04-01 2020-06-30 0000315545 us-gaap:SeriesBPreferredStockMember 2020-03-31 0000315545 us-gaap:SeriesBPreferredStockMember 2019-03-31 0000315545 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000315545 us-gaap:CommonStockMember 2020-03-31 0000315545 us-gaap:CommonStockMember 2019-03-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000315545 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000315545 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000315545 us-gaap:RetainedEarningsMember 2020-03-31 0000315545 us-gaap:RetainedEarningsMember 2019-03-31 0000315545 2020-03-31 0000315545 2019-03-31 0000315545 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-03-31 0000315545 us-gaap:SeriesBPreferredStockMember 2019-01-01 2019-03-31 0000315545 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0000315545 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0000315545 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0000315545 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0000315545 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0000315545 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000315545 2020-01-01 2020-03-31 0000315545 2019-01-01 2019-03-31 0000315545 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000315545 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000315545 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0000315545 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-06-30 0000315545 PVCT:MrBruceHorowitzMember 2020-04-01 2020-06-30 0000315545 PVCT:MrBruceHorowitzMember 2019-04-01 2019-06-30 0000315545 PVCT:PaycheckProtectionProgramMember PVCT:TheCARESActMember 2020-04-19 2020-04-20 0000315545 PVCT:PaycheckProtectionProgramMember PVCT:TheCARESActMember 2020-01-01 2020-06-30 0000315545 PVCT:EconomicInjuryDisasterLoanMember 2020-01-01 2020-06-30 0000315545 PVCT:ConsultantMember 2020-01-01 2020-06-30 0000315545 us-gaap:SubsequentEventMember 2020-07-01 2020-08-07 0000315545 us-gaap:SubsequentEventMember 2020-08-07 0000315545 PVCT:MrBruceHorowitzMember 2020-06-30 0000315545 PVCT:MrBruceHorowitzMember 2019-06-30 0000315545 us-gaap:SubsequentEventMember PVCT:TwoThousandTwentyFinancingMember 2020-07-01 2020-08-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure utr:sqft PROVECTUS BIOPHARMACEUTICALS, INC. 0000315545 10-Q 2020-06-30 false Non-accelerated Filer

590706

1483214

64630

71676

11487338

11715455

0.001

25000000

240000

25000000

240000

0.001

1000000000

389889475

390714475

389889475

390714475

1605900

2245655

1208324

696454

1053188

1390316

631063

514394

-2659088

-3635971

-1839387

-1210848

3413

21905

19650

3334

390635608

384769219

384773639

390714200

7046

42622

228107

335560

-47653

-49863

332134

-1757954

3500

100000 25000

2375000

4825000

42640

5330

194438

-0.01

-0.00

350249

142659

996013

1629650

228107

58384

51338

1125890

1457729

1255266

1376008

3022912

29189533

25549016

29315569

389889

390714

209378835

209421800

-233816828

-237258694

1476904

1838587

394362475 Q2 --12-31

-1684096

-3557229

2580140

4855330

675000

26364 82941 -1131 113

true false

1226582

-207590

-127794

120817

481936

100

892508

1273242

50986

590706

1324228

1483214

1476904

1838587

-17417489

384615

209092187

-226894291

-24072112

389889

209378835

-233816828

-24008

384906

209116301

-24859

-230441440

-20965092

-27476982

390714

209421800

-30802

-237258694

390689

384715

209420675

209097417

-33035

-22363

-235643889

-228264121

-25865560

-18804352

384614528

100

389889475

100

384906118

100

390714475

100

390689475

384714528

800 100 41840 5230 42640 5330 800000 100000

-3441866

-3547149

-2177319

-1614805

-1827061

-1369830

-1827061

-1369830

1501864

12997000

55058

3777

194400

157599

76423

81149

130658

86974

-24008

-30802

2659088

3635971

1839387

1210848

-30802

-24859

-2496

2233

-9027

-22363

-9027

-22363

-3536

-24859

1150

19075

4500

P5Y

2022-06-30

44882

7300

7800

P2Y

0.080

500000

100000

2475000

15872000

Yes false Yes

6670000

815430

691024

815555

691024

356451

410404

3. Critical Accounting Policies   Since the date the Company’s December 31, 2019 consolidated financial statements were issued in its 2019 Annual Report, there have been no material changes to the Company’s significant accounting policies, except as disclosed below.   Recently Issued Accounting Standards   In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its condensed consolidated financial statements and related disclosures.   The CARES Act   On March 27, 2020, President Trump signed the CARES Act into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. Under ASC 740 of GAAP, the effects of new legislation are recognized upon enactment. Accordingly, the CARES Act is effective beginning in the quarter ended March 31, 2020. The adoption of the CARES Act provisions did not have a material impact on the Company’s condensed consolidated financial statements.

4. Convertible Notes Payable   2020 Financing   On December 31, 2019, the Board approved a Definitive Financing Term Sheet (the “2020 Term Sheet”), which sets forth the terms under which the Company will use its best efforts to arrange for financing of a maximum of $20,000,000 (the “2020 Financing”). The 2020 Financing will be in the form of secured convertible loans (“Loans”) from investors that will be evidenced by convertible promissory notes (the “2020 Notes”). Subject to the terms and conditions of the 2020 Term Sheet, the Company will use its best efforts to arrange for the 2020 Financing, which amounts will be obtained in several tranches. The proceeds from the 2020 Financing will be used to fund the Company’s clinical development program, as currently constituted and envisioned, and to fund the Company’s general and administrative expenses.   Since the 2020 Financing was launched and through June 30, 2020, the Company had received aggregate Loans of $2,575,000.   The Series D Preferred Stock   As of June 30, 2020, and through the date of filing, the Series D Preferred Stock had not been designated by the Board. Per the terms of the notes issued in connection with the 2017 and 2020 Financings, if the Company has not designated the Series D Preferred Stock or if an insufficient number of Series D Preferred shares exist upon a conversion by a note holder, then the outstanding loans will continue to accrue interest at a rate of 8% per annum until which time the Company has designated a sufficient number of Series D Preferred shares. As a result, the Company did not analyze the notes for a potential beneficial conversion feature as the definition of a firm commitment has not been met since the notes were not convertible as of their respective dates of issuance or as of June 30, 2020.   Convertible Notes Payable – Related Parties   During the six months ended June 30, 2020, the Company entered into additional related party 2020 Notes in the aggregate principal amount of $100,000. As of June 30, 2020, the Company had borrowed $100,000 under these notes.   Convertible Notes Payable – Non-Related Parties   During the six months ended June 30, 2020, the Company entered into additional non-related party 2020 Notes in the aggregate principal amount of $2,375,000. As of June 30, 2020, the Company had borrowed $2,475,000   under these notes.   Notes Payable   On April 20, 2020, the Company received a $62,500 loan under the CARES Act PPP (the “PPP Loan”). The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower’s average monthly payroll expenses. The loan principal and accrued interest are forgivable, as long as the borrower uses loan proceeds for eligible uses during a specified period following disbursement, such as payroll, benefits, rent, and utilities, and maintains specified headcount and payroll thresholds. If any portion of a PPP Loan is not forgiven, the unforgiven portion is payable over two years at an interest rate of 1%, with a deferral of payments for the first seven months. The Company intends to use PPP Loan proceeds in a manner that it believes presently qualifies for full forgiveness. We cannot provide assurance that the PPP Loan will be forgiven in full As of June 30, 2020, the Company had not applied for forgiveness of the PPP Loan.   Once an amount is forgiven under the PPP Loan, the Company intends to recognize a gain on forgiveness of note payable in the period in which it obtained forgiveness.

6. Receivables   The following table summarizes the receivables at June 30, 2020 and December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Tax Credit</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Legal Fees</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Settlement</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Provectus Australia Tax Credit</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,777</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,777</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gross receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">455,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,649,043</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,104,543</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Reserve for uncollectibility</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(455,500</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,649,043</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,104,543</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,777</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,777</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Tax Credit</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Legal Fees</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Settlement</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Provectus Australia Tax Credit</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">55,058</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">55,058</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gross receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">455,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,649,043</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,104,543</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Reserve for uncollectibility</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(455,500</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,649,043</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,104,543</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">55,058</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">55,058</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

184943

168123

16819

65333

2114852

-38958

0.0533

800000

3648000

43634

29090

14544

38089

19045

57134

22329

22332

14888

14886

7444

7443

-3472668

-3572008

-2179815

-1612572

Recently Issued Accounting Standards   In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-03, Codification Improvements to Financial Instruments. There are seven issues addressed in this update. Issues 1 – 5 were clarifications and codifications of previous updates. Issue 3 relates only to depository and lending institutions and therefore would not be applicable to the Company. Issue 6 was a clarification on determining the contractual term of a net investment in a lease for purposes of measuring expected credit losses, an issue not applicable to the Company. Issue 7 relates to the regaining control of financial assets sold and the recordation of an allowance for credit losses. The amendment related to issues 1, 2, 4 and 5 became effective immediately upon adoption of the update. Issue 3 becomes effective for fiscal years beginning after December 15, 2019. Issues 6 and 7 become effective on varying dates that relate to the dates of adoption of other updates. Management’s initial analysis is that it does not believe the new guidance will substantially impact the Company’s financial statements. The Company adopted certain provisions which have become effective during fiscal 2020 within ASU 2020-03 and its adoption did not have a material impact on the Company’s condensed consolidated financial statements and financial statement disclosures. The Company is currently evaluating the effect that adopting the remaining new accounting guidance will have on its condensed consolidated financial statements and related disclosures.   The CARES Act   On March 27, 2020, President Trump signed the CARES Act into law. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, and technical corrections to tax depreciation methods for qualified improvement property. Under ASC 740 of GAAP, the effects of new legislation are recognized upon enactment. Accordingly, the CARES Act is effective beginning in the quarter ended March 31, 2020. The adoption of the CARES Act provisions did not have a material impact on the Company’s condensed consolidated financial statements.

36801

2104543

227750

252750 2020

8. Leases   The Company currently leases 4,500 square feet of corporate office space in Knoxville, Tennessee through an operating lease agreement for a term of five years ending on June 30, 2022. Payments range from approximately $7,300 to $7,800 per month.   Total operating lease expense for the three months ended June 30, 2020 was $22,332, of which, $14,888 was included within research and development and $7,444 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the three months ended June 30, 2019 was $22,329, of which, $14,886 was included within research and development and $7,443 was included within general and administrative expenses on the condensed consolidated statement of operations.   Total operating lease expense for the six months ended June 30, 2020 was $43,634, of which, $29,090 was included within research and development and $14,544 was included within general and administrative expenses on the condensed consolidated statement of operations. Total operating lease expense for the six months ended June 30, 2019 was $57,134, of which, $38,089 was included within research and development and $19,045 was included within general and administrative expenses on the condensed consolidated statement of operations.    As of June 30, 2020, the Company had no leases that were classified as a financing lease. As of June 30, 2020, the Company did not have additional operating and financing leases that have not yet commenced.    A summary of the Company’s right-of-use assets and liabilities is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Six Months Ended June 30, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cash paid for amounts included in the measurement of lease liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 77%; padding-left: 10pt">Operating cash flows used in operating leases</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">44,882</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Right-of-use assets obtained in exchange for lease obligations:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Operating leases</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Weighted Average Remaining Lease Term</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Operating leases</td> <td> </td> <td> </td> <td style="text-align: right">2.0 Years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted Average Discount Rate</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Operating leases</td> <td> </td> <td> </td> <td style="text-align: right">8.0</td> <td>%</td></tr> </table>   Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2020 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Years</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">45,784</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">92,471</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">2022</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,687</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Total future minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">184,943</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt">Less: amount representing imputed interest</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(16,819</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">168,123</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

42640

2240000

45784

46687

92471

-782778

88822

-337932

-403957

1494357

6770000

3000 3000

191590

25000

191

8771

8962

1150

1125

10113

62500

The following table summarizes the receivables at June 30, 2020 and December 31, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">June 30, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Tax Credit</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Legal Fees</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Settlement</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Provectus Australia Tax Credit</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,777</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">3,777</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gross receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">455,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,649,043</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,104,543</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Reserve for uncollectibility</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(455,500</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,649,043</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,104,543</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,777</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">3,777</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Tax Credit</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Legal Fees</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Settlement</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 48%">Provectus Australia Tax Credit</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">55,058</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">55,058</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Gross receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">455,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,649,043</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,104,543</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Reserve for uncollectibility</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(455,500</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,649,043</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(2,104,543</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Net receivable</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">55,058</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">-</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">55,058</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

800000

55058

3777

2104543

455500

1649043

2104543

455500

1649043

2104543

455500

1649043

2104543

455500

1649043

55058

3777

63600

171200

11200

61200

20000000

2575000

62500

3000

450000

0.08

0.01

100000

2375000

P2Y

The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower's average monthly payroll expenses.

23438

39062

25000

1150

A summary of the Company’s right-of-use assets and liabilities is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Six Months Ended June 30, 2020</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cash paid for amounts included in the measurement of lease liabilities:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 77%; padding-left: 10pt">Operating cash flows used in operating leases</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 20%; text-align: right">44,882</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Right-of-use assets obtained in exchange for lease obligations:</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Operating leases</td> <td> </td> <td>$</td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Weighted Average Remaining Lease Term</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Operating leases</td> <td> </td> <td> </td> <td style="text-align: right">2.0 Years</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Weighted Average Discount Rate</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-left: 10pt">Operating leases</td> <td> </td> <td> </td> <td style="text-align: right">8.0</td> <td>%</td></tr> </table>

Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2020 were as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Years</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 77%">2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 20%; text-align: right">45,784</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>2021</td> <td> </td> <td> </td> <td style="text-align: right">92,471</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">2022</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">46,687</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-left: 10pt">Total future minimum lease payments</td> <td> </td> <td> </td> <td style="text-align: right">184,943</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt; padding-left: 20pt">Less: amount representing imputed interest</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(16,819</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Total</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">168,123</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

9. Commitments, Contingencies and Litigation   Culpepper Travel Expenses and Related Collection Efforts   On December 27, 2016, the then-Board of Directors (the “then-Board”) unanimously voted to terminate then-interim Chief Executive Officer, then-Chief Operating Officer, and former Chief Financial Officer, Peter Culpepper (“Culpepper”), effective immediately, from all positions he held with the Company and each of its subsidiaries, “for cause,” in accordance with the terms of the Amended and Restated Executive Employment Agreement entered into by Culpepper and the Company on April 28, 2014 (the “Culpepper Employment Agreement”), based on the results of the investigation conducted by the Audit Committee of the then-Board regarding improper expense reimbursements to Culpepper.   The Company took the position that under the terms of the Culpepper Employment Agreement, Culpepper is owed no severance payments as a result of his termination “for cause” as that term is defined in the Culpepper Employment Agreement. Furthermore, Culpepper is no longer entitled to the 2:1 credit under the Stipulated Settlement Agreement and Mutual Release in the Kleba Derivative Lawsuit Settlement (the “Derivative Lawsuit Settlement”) such that the total $2,240,000 owed by Culpepper pursuant to the Derivative Lawsuit Settlement plus Culpepper’s proportionate share of the litigation cost in the amount of $227,750, less the amount that he repaid as of December 31, 2016, is immediately due and payable. The Company sent Culpepper a notice of default in January 2017 for the total amount he owes the Company and is in the process of pursuing these claims in accordance with the alternative dispute resolution provision of the Culpepper Employment Agreement. The Company has established a reserve of $2,104,543 as of June 30, 2020 and December 31, 2019, which amount represents the amount the Company currently believes Culpepper owes to the Company under the Derivative Lawsuit Settlement (excluding the amount of attorneys’ fees incurred in enforcing the terms of the Derivative Lawsuit Settlement), while the Company pursues collection of this amount.   Culpepper disputed that he was terminated “for cause” under the Culpepper Employment Agreement. On June 28, 2017, pursuant to the alternative dispute resolution provisions of that agreement, the Company and Culpepper participated in a mediation of their dispute. Having reached no resolution during the mediation, the parties participated in arbitration under the commercial rules of the American Arbitration Association, arbitrating Culpepper’s claim against the Company for severance and the Company’s claims against Culpepper for improper expense reimbursements and amounts Culpepper owed the Company under the Derivative Lawsuit Settlement. On September 12, 2018, the arbitrator issued his final award in favor of the Company.   On October 4, 2018, the Company filed a petition with the Chancery Court for Davidson County, Tennessee to confirm the arbitration award. On January 23, 2019, the Chancery Court entered an order confirming the arbitrator’s award. On February 20, 2019, Culpepper filed a motion to alter or amend the Chancery Court’s judgment. On March 22, 2019, the Chancery Court upheld the arbitration award in favor of the Company.   On April 16, 2019, Culpepper filed a Notice of Appeal with the Tennessee Court of Appeals regarding the Chancery Court’s judgment. The Company and Culpepper submitted their respective court of appeal briefs on November 12, 2019 and December 3, 2019, respectively. Oral arguments were held on January 7, 2020. On April 14, 2020, the Court of Appeals affirmed the Chancery Court’s judgment and awarded court costs to the Company.   On June 16, 2020, Culpepper filed an application to the Supreme Court of Tennessee for permission to appeal the Court of Appeals’ final decision. On June 30, 2020, the Company filed an answer to the Supreme Court in opposition to Culpepper’s application for permission to appeal. On August 5, 2020, the Supreme Court denied Culpepper’s application.

5. Related Party Transactions   During the three and six months ended June 30, 2020, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $11,200 and $63,600, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of June 30, 2020 were $37,500.   During the three and six months ended June 30, 2019, the Company paid Mr. Bruce Horowitz (Capital Strategists) consulting fees of $61,200 and $171,200, respectively, for services rendered. Accrued director fees for Mr. Horowitz as of June 30, 2019 were $37,500. Mr. Horowitz serves as both COO and a Director.   See Note 4 and Note 6 for details of other related party transactions.

1. Business Organization, Nature of Operations and Basis of Presentation   Provectus Biopharmaceuticals, Inc., a Delaware corporation (together with its subsidiaries, “Provectus” or the “Company”), is a clinical-stage biotechnology company that is developing immunotherapy medicines based on an entire, wholly-owned family of small molecules called halogenated xanthenes. The Company’s proprietary lead molecule is current Good Manufacturing Practice (“cGMP”) rose bengal disodium (“RBD”).   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px"> </td> <td style="width: 24px">●</td> <td style="text-align: justify">Oncology: PV-10, an investigational autolytic cancer immunotherapy administered by intralesional (“IL”) injection and formulation of cGMP RBD, is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal (“GI”) tumors (including hepatocellular carcinoma (“HCC”), colorectal cancer metastatic to the liver (“mCRC”), neuroendocrine tumors (“NET”) metastatic to the liver (“mNET”), and uveal melanoma metastatic to the liver (“mUM”), among others). Orphan drug designation status has been granted to IL PV-10 by the U.S. Food and Drug Administration (the “FDA”) for metastatic melanoma in 2006, HCC in 2011, and ocular melanoma (including uveal melanoma) in 2019.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Pediatric Oncology: IL PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). Orphan drug designation status has been granted to IL PV-10 by the FDA for neuroblastoma in 2018.</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Hematology: A new systemically-administered formulation of cGMP RBD is undergoing preclinical study for pediatric blood cancers (including leukemia).</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Virology: A new systemically-administered formulation of cGMP RBD is undergoing preclinical study for the novel strain of coronavirus (“CoV”), severe acute respiratory syndrome (“SARS”) CoV 2 (“SARS-CoV-2”).</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td style="text-align: justify">Dermatology: PH-10, an investigational immuno-dermatology agent administered as a topical (“top.”) gel and formulation of cGMP RBD, is undergoing clinical study for inflammatory dermatoses (including psoriasis and atopic dermatitis).</td></tr> </table>   To date, the Company has not generated any revenues or profits from planned principal operations. The Company’s activities are subject to significant risks and uncertainties, including failing to successfully develop and license or commercialize the Company’s prescription drug candidates.   The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information pursuant to Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements and should be reviewed in conjunction with the Company’s audited consolidated financial statements included in the Company’s Form 10-K for the year ended December 31, 2019 filed with the SEC on March 5, 2020. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020.   SARS-CoV-2 was reportedly first identified in late-2019 and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. As a result of the SARS-CoV-2 pandemic, many companies have experienced disruptions of their operations and the markets they serve. The Company has taken several temporary precautionary measures intended to help ensure the well-being of its employees and contractors and to minimize business disruption. The Company considered the impact of SARS-CoV-2 pandemic on its business and operational assumptions and estimates, and determined there were no material adverse impacts on the Company’s results of operations and financial position at June 30, 2020.   The full extent of the SARS-CoV-2 pandemic impacts on the Company’s operations and financial condition is uncertain. A prolonged SARS-CoV-2 pandemic could have a material adverse impact on the Company’s business and financial results, including the timing and ability of the Company to initiate and/or complete current and/or future preclinical studies and/or clinical trials; disrupt the Company’s regulatory activities; and/or have other adverse effects on the Company’s clinical development.

37500

2. Liquidity and Going Concern   The Company’s cash and cash equivalents were $1,483,214 at June 30, 2020. The Company continues to incur significant operating losses. Management expects that significant on-going operating expenditures will be necessary to successfully implement the Company’s business plan and develop and market its products. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. Implementation of the Company’s plans and its ability to continue as a going concern will depend upon the Company’s ability to develop IL PV-10, top. PH-10, and/or any other halogenated xanthene-based drug products, and to raise additional capital.   During the six months ended June 30, 2020, the Company received a loan of $62,500 under the Paycheck Protection Program (“PPP”) (see Note 4) and received a grant of $3,000 from the Economic Injury Disaster Loan (“EIDL”) under the CARES Act. The grant was recognized as other income during the three and six months ended June 30, 2020.   Subsequent to June 30, 2020, the Company received an aggregate $194,438 in connection with a warrant exercise. The Company also received an aggregate $450,000 in connection with the 2020 Financing. See Note 10 – Subsequent Events.   The Company plans to access capital resources through possible public or private equity offerings, including the 2020 Financing (as defined in Note 4), exchange offers, debt financings, corporate collaborations or other means. In addition, the Company continues to explore opportunities to strategically monetize its lead drug candidates, IL PV-10 and top. PH-10, through potential co-development and licensing transactions, although there can be no assurance that the Company will be successful with such plans. The Company has historically been able to raise capital through equity offerings, although no assurance can be provided that it will continue to be successful in the future. If the Company is unable to raise sufficient capital through the 2020 Financing or otherwise, it will not be able to pay its obligations as they become due.   The primary business objective of management is to build the Company into a commercial-stage biotechnology company; however, the Company cannot assure you that it will be successful in developing further, co-developing, licensing, and/or commercializing IL PV-10, top. PH-10, and/or any other halogenated xanthene-based drug products of the Company, or entering into any commercial financial transaction. Moreover, even if the Company is successful in improving its current cash flow position, the Company nonetheless plans to seek additional funds to meet its long-term requirements in 2020 and beyond. The Company anticipates that these funds will otherwise come from the proceeds of private placement transactions, including the 2020 Financing, the exercise of existing warrants and outstanding stock options, or public offerings of debt or equity securities. While the Company believes that it has a reasonable basis for its expectation that it will be able to raise additional funds, the Company cannot assure you that it will be able to complete additional financing in a timely manner. In addition, any such financing may result in significant dilution to stockholders.

7. Stockholders’ Deficiency   Common Stock   During the six months ended June 30, 2020, warrant holders exercised warrants to purchase an aggregate of 800,000 shares of common stock at an exercise price of $0.0533 per share. In connection with these exercises, the Company received aggregate cash proceeds of $42,640 and issued 800,000 shares of common stock to the holders. Subsequent to June 30, 2020, the Company received an aggregate $194,438 in connection with a warrant exercise. See Note 10 – Subsequent Events.   During the six months ended June 30, 2020, the Company issued an aggregate of 25,000 shares of immediately vested restricted common stock to a consultant with an issuance date fair value of $1,150, which was recognized immediately.

10. Subsequent Events   Convertible Notes Payable   Subsequent to June 30, 2020, the Company entered into a 2020 Note with a non-related party in the aggregate principal amount of $450,000 in connection with a 2nd Loan received by the Company for the same amount.   Exercise of Warrants   Subsequent to June 30, 2020, a warrant holder exercised warrants to purchase an aggregate of 3,648,000 shares of common stock at $0.0533 per share. In connection with this exercise, the Company received aggregate cash proceeds of $194,438.

EX-101.SCH 6 pvct-20200630.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Liquidity and Going Concern link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Critical Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Convertible Notes Payable link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Receivables link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Deficiency link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Commitments, Contingencies and Litigation link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Critical Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Receivables (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Liquidity and Going Concern (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Convertible Notes Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Receivables - Summary of Receivables (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Stockholders' Deficiency (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Leases (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Leases - Schedule of Right-of-use Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Commitments, Contingencies and Litigation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 pvct-20200630_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 pvct-20200630_def.xml XBRL DEFINITION FILE EX-101.LAB 9 pvct-20200630_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-In Capital [Member] Accumulated Deficit [Member] Class of Stock [Axis] Preferred Stock Series B [Member] Series B Convertible Preferred Stock [Member] Accumulated Other Comprehensive Loss [Member] Geographical [Axis] Knoxville, Tennessee [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Range [Axis] Minimum [Member] Maximum [Member] Receivable Type [Axis] Legal Fees [Member] Settlement [Member] Plan Name [Axis] 2020 Financing [Member] Debt Instrument [Axis] 2020 Notes [Member] Related Party [Axis] Related Party [Member] Title of Individual [Axis] Mr Bruce Horowitz [Member] Income Tax Authority, Name [Axis] Provectus Australia [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Culpepper Employment Agreement [Member] Peter Culpepper [Member] 2017 and 2020 Financings [Member] Non-Related Party [Member] Warrant Holders [Member] Legal Entity [Axis] Paycheck Protection Program [Member] Award Type [Axis] The CARES Act [Member] Economic Injury Disaster Loan [Member] Consultant [Member] Subsequent Event Type [Axis] Subsequent Event [Member] 2020 Financing [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Reporting Status Current Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Short-term receivables - legal fees, settlement and other, net Prepaid expenses Total Current Assets Equipment and furnishings, less accumulated depreciation of $71,676 and $64,630, respectively Operating lease right-of-use asset Patents, net of accumulated amortization of $11,715,455 and $11,487,338, respectively Total Assets Liabilities and Stockholders' Deficiency Current Liabilities: Accounts payable - trade Other accrued expenses Current portion of accrued interest Current portion of accrued interest - related parties Current portion of note payable Current portion of convertible notes payable Current portion of convertible notes payable - related parties Current portion of operating lease liability Total Current Liabilities Accrued interest, non-current portion Accrued interest, non-current portion - related parties Note payable, non-current portion Convertible notes payable, non-current portion Convertible notes payable, non-current portion - related parties Operating lease liability, non-current portion Total Liabilities Commitments and contingencies (Note 9) Stockholders' Deficiency: Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at June 30, 2020 and December 31, 2019; aggregate liquidation preference of $3,500 at June 30, 2020 and December 31, 2019 Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 390,714,475 and 389,889,475 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Total Stockholders' Deficiency Total Liabilities and Stockholders' Deficiency Statement [Table] Statement [Line Items] Accumulated depreciation on equipment and furnishings Accumulated amortization on patents Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Aggregate liquidation preference Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Research and development General and administrative Total Operating Expenses Total Operating Loss Other Income/(Expense): EIDL grant Gain on settlement of lawsuits Research and development tax credit Investment and interest income Interest expense Total Other Income/(Expense) Net Loss Basic and Diluted Loss Per Common Share Weighted Average Number of Common Shares Outstanding - Basic and Diluted Net Loss Other Comprehensive Income (Loss): Foreign currency translation adjustments Total Comprehensive Loss Beginning Balance Beginning Balance, shares Common stock issued upon exercise of warrants Common stock issued upon exercise of warrants, shares Common stock issued for services Common stock issued for services, shares Warrants issued for services Net loss Other comprehensive loss Ending Balance Ending Balance, shares Statement of Cash Flows [Abstract] Cash Flows From Operating Activities: Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Noncash lease expense Depreciation Amortization of patents Changes in operating assets and liabilities Short term receivables Prepaid expenses Accounts payable - trade Other accrued expenses Operating lease liability Accrued interest expense Net Cash Used In Operating Activities Cash Flows From Financing Activities: Proceeds from issuance of convertible notes payable Proceeds from issuance of convertible notes payable - related parties Proceeds from note payable Proceeds from exercise of warrants Net Cash Provided By Financing Activities Effect of Exchange Rate Changes on Cash Net Increase In Cash and Cash Equivalents Cash and Cash Equivalents, Beginning of Period Cash and Cash Equivalents, End of Period Supplemental Disclosures of Cash Flow Information: Cash paid during the period for: Interest Income taxes Non-cash investing and financing activities: Offset of related party receivable and payable Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Organization, Nature of Operations and Basis of Presentation Liquidity and Going Concern Accounting Policies [Abstract] Critical Accounting Policies Debt Disclosure [Abstract] Convertible Notes Payable Related Party Transactions [Abstract] Related Party Transactions Receivables [Abstract] Receivables Equity [Abstract] Stockholders' Deficiency Leases [Abstract] Leases Commitments and Contingencies Disclosure [Abstract] Commitments, Contingencies and Litigation Subsequent Events [Abstract] Subsequent Events Recently Issued Accounting Standards Summary of Receivables EX-101.PRE 10 pvct-20200630_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	6 Months Ended
Document and Entity Information - shares	Jun. 30, 2020	Aug. 11, 2020
Cover [Abstract]
Entity Registrant Name	PROVECTUS BIOPHARMACEUTICALS, INC.
Entity Central Index Key	0000315545
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Reporting Status Current	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		394,362,475
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 1,483,214	$ 590,706
Short-term receivables - legal fees, settlement and other, net	3,777	55,058
Prepaid expenses	142,659	350,249
Total Current Assets	1,629,650	996,013
Equipment and furnishings, less accumulated depreciation of $71,676 and $64,630, respectively	51,338	58,384
Operating lease right-of-use asset	157,599	194,400
Patents, net of accumulated amortization of $11,715,455 and $11,487,338, respectively		228,107
Total Assets	1,838,587	1,476,904
Current Liabilities:
Accounts payable - trade	1,457,729	1,125,890
Other accrued expenses	1,376,008	1,255,266
Current portion of accrued interest	2,114,852	65,333
Current portion of accrued interest - related parties	1,494,357
Current portion of note payable	23,438
Current portion of convertible notes payable	15,872,000	500,000
Current portion of convertible notes payable - related parties	6,770,000
Current portion of operating lease liability	81,149	76,423
Total Current Liabilities	29,189,533	3,022,912
Accrued interest, non-current portion		1,501,864
Accrued interest, non-current portion - related parties		1,226,582
Note payable, non-current portion	39,062
Convertible notes payable, non-current portion		12,997,000
Convertible notes payable, non-current portion - related parties		6,670,000
Operating lease liability, non-current portion	86,974	130,658
Total Liabilities	29,315,569	25,549,016
Commitments and contingencies (Note 9)
Stockholders' Deficiency:
Preferred stock; par value $0.001 per share; 25,000,000 shares authorized; Series B Convertible Preferred Stock; 240,000 shares designated; 100 shares issued and outstanding at June 30, 2020 and December 31, 2019; aggregate liquidation preference of $3,500 at June 30, 2020 and December 31, 2019
Common stock; par value $0.001 per share; 1,000,000,000 shares authorized; 390,714,475 and 389,889,475 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively	390,714	389,889
Additional paid-in capital	209,421,800	209,378,835
Accumulated other comprehensive loss	(30,802)	(24,008)
Accumulated deficit	(237,258,694)	(233,816,828)
Total Stockholders' Deficiency	(27,476,982)	(24,072,112)
Total Liabilities and Stockholders' Deficiency	$ 1,838,587	$ 1,476,904

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Accumulated depreciation on equipment and furnishings	$ 71,676	$ 64,630
Accumulated amortization on patents	$ 11,715,455	$ 11,487,338
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	25,000,000	25,000,000
Aggregate liquidation preference	$ 3,500	$ 3,500
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,000,000,000	1,000,000,000
Common stock, shares issued	390,714,475	389,889,475
Common stock, shares outstanding	390,714,475	389,889,475
Series B Convertible Preferred Stock [Member]
Preferred stock, shares authorized	240,000	240,000
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Operating Expenses:
Research and development	$ 696,454	$ 1,208,324	$ 1,605,900	$ 2,245,655
General and administrative	514,394	631,063	1,053,188	1,390,316
Total Operating Expenses	1,210,848	1,839,387	2,659,088	3,635,971
Total Operating Loss	(1,210,848)	(1,839,387)	(2,659,088)	(3,635,971)
Other Income/(Expense):
EIDL grant	3,000		3,000
Gain on settlement of lawsuits				675,000
Research and development tax credit	113	(1,131)	26,364	82,941
Investment and interest income	3,334	19,650	3,413	21,905
Interest expense	(410,404)	(356,451)	(815,555)	(691,024)
Total Other Income/(Expense)	(403,957)	(337,932)	(782,778)	88,822
Net Loss	$ (1,614,805)	$ (2,177,319)	$ (3,441,866)	$ (3,547,149)
Basic and Diluted Loss Per Common Share	$ (0.00)	$ (0.01)	$ (0.01)	$ (0.01)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	390,714,200	384,773,639	390,635,608	384,769,219

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
Net Loss	$ (1,614,805)	$ (2,177,319)	$ (3,441,866)	$ (3,547,149)
Other Comprehensive Income (Loss):
Foreign currency translation adjustments	2,233	(2,496)	(30,802)	(24,859)
Total Comprehensive Loss	$ (1,612,572)	$ (2,179,815)	$ (3,472,668)	$ (3,572,008)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended				6 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2019	Mar. 31, 2019	Jun. 30, 2020	Jun. 30, 2019
Preferred Stock Series B [Member]
Beginning Balance
Beginning Balance, shares	100	100	100	100	100	100
Common stock issued upon exercise of warrants
Common stock issued upon exercise of warrants, shares
Common stock issued for services
Common stock issued for services, shares
Warrants issued for services
Net loss
Other comprehensive loss
Ending Balance
Ending Balance, shares	100	100	100	100	100	100
Common Stock [Member]
Beginning Balance	$ 390,689	$ 389,889	$ 384,715	$ 384,615	$ 389,889	$ 384,615
Beginning Balance, shares	390,689,475	389,889,475	384,714,528	384,614,528	389,889,475	384,614,528
Common stock issued upon exercise of warrants		$ 800		$ 100
Common stock issued upon exercise of warrants, shares		800,000		100,000
Common stock issued for services	$ 25		$ 191
Common stock issued for services, shares	25,000		191,590
Warrants issued for services
Net loss
Other comprehensive loss
Ending Balance	$ 390,714	$ 390,689	$ 384,906	$ 384,715	$ 390,714	$ 384,906
Ending Balance, shares	390,714,475	390,689,475	384,906,118	384,714,528	390,714,475	384,906,118
Additional Paid-In Capital [Member]
Beginning Balance	$ 209,420,675	$ 209,378,835	$ 209,097,417	$ 209,092,187	$ 209,378,835	$ 209,092,187
Common stock issued upon exercise of warrants		41,840		5,230
Common stock issued for services	1,125		8,771
Warrants issued for services			10,113
Net loss
Other comprehensive loss
Ending Balance	209,421,800	209,420,675	209,116,301	209,097,417	209,421,800	209,116,301
Accumulated Other Comprehensive Loss [Member]
Beginning Balance	(33,035)	(24,008)	(22,363)		(24,008)
Common stock issued upon exercise of warrants
Common stock issued for services
Warrants issued for services
Net loss
Other comprehensive loss	2,233	(9,027)	(2,496)	(22,363)
Ending Balance	(30,802)	(33,035)	(24,859)	(22,363)	(30,802)	(24,859)
Accumulated Deficit [Member]
Beginning Balance	(235,643,889)	(233,816,828)	(228,264,121)	(226,894,291)	(233,816,828)	(226,894,291)
Common stock issued upon exercise of warrants
Common stock issued for services
Warrants issued for services
Net loss	(1,614,805)	(1,827,061)	(2,177,319)	(1,369,830)
Other comprehensive loss
Ending Balance	(237,258,694)	(235,643,889)	(230,441,440)	(228,264,121)	(237,258,694)	(230,441,440)
Beginning Balance	(25,865,560)	(24,072,112)	(18,804,352)	(17,417,489)	(24,072,112)	(17,417,489)
Common stock issued upon exercise of warrants		42,640		5,330
Common stock issued for services	1,150		8,962
Warrants issued for services			10,113
Net loss	(1,614,805)	(1,827,061)	(2,177,319)	(1,369,830)	(3,441,866)	(3,547,149)
Other comprehensive loss	2,233	(9,027)	(2,496)	(22,363)	(30,802)	(24,859)
Ending Balance	$ (27,476,982)	$ (25,865,560)	$ (20,965,092)	$ (18,804,352)	$ (27,476,982)	$ (20,965,092)

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Cash Flows From Operating Activities:
Net loss	$ (3,441,866)	$ (3,547,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,150	19,075
Noncash lease expense	36,801
Depreciation	7,046	42,622
Amortization of patents	228,107	335,560
Changes in operating assets and liabilities
Short term receivables	47,653	49,863
Prepaid expenses	207,590	127,794
Accounts payable - trade	332,134	(1,757,954)
Other accrued expenses	120,817	481,936
Operating lease liability	(38,958)
Accrued interest expense	815,430	691,024
Net Cash Used In Operating Activities	(1,684,096)	(3,557,229)
Cash Flows From Financing Activities:
Proceeds from issuance of convertible notes payable	2,375,000	4,825,000
Proceeds from issuance of convertible notes payable - related parties	100,000	25,000
Proceeds from note payable	62,500
Proceeds from exercise of warrants	42,640	5,330
Net Cash Provided By Financing Activities	2,580,140	4,855,330
Effect of Exchange Rate Changes on Cash	(3,536)	(24,859)
Net Increase In Cash and Cash Equivalents	892,508	1,273,242
Cash and Cash Equivalents, Beginning of Period	590,706	50,986
Cash and Cash Equivalents, End of Period	1,483,214	1,324,228
Cash paid during the period for:
Interest
Income taxes
Non-cash investing and financing activities:
Offset of related party receivable and payable		$ 252,750

XML 18 R8.htm IDEA: XBRL DOCUMENT

Business Organization, Nature of Operations and Basis of Presentation

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Business Organization, Nature of Operations and Basis of Presentation

1. Business Organization, Nature of Operations and Basis of Presentation

	●	Oncology: PV-10, an investigational autolytic cancer immunotherapy administered by intralesional (“IL”) injection and formulation of cGMP RBD, is undergoing clinical study for adult solid tumor cancers, like melanoma and gastrointestinal (“GI”) tumors (including hepatocellular carcinoma (“HCC”), colorectal cancer metastatic to the liver (“mCRC”), neuroendocrine tumors (“NET”) metastatic to the liver (“mNET”), and uveal melanoma metastatic to the liver (“mUM”), among others). Orphan drug designation status has been granted to IL PV-10 by the U.S. Food and Drug Administration (the “FDA”) for metastatic melanoma in 2006, HCC in 2011, and ocular melanoma (including uveal melanoma) in 2019.

	●	Pediatric Oncology: IL PV-10 is also undergoing preclinical study for pediatric solid tumor cancers (including neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma). Orphan drug designation status has been granted to IL PV-10 by the FDA for neuroblastoma in 2018.

	●	Hematology: A new systemically-administered formulation of cGMP RBD is undergoing preclinical study for pediatric blood cancers (including leukemia).

	●	Virology: A new systemically-administered formulation of cGMP RBD is undergoing preclinical study for the novel strain of coronavirus (“CoV”), severe acute respiratory syndrome (“SARS”) CoV 2 (“SARS-CoV-2”).

	●	Dermatology: PH-10, an investigational immuno-dermatology agent administered as a topical (“top.”) gel and formulation of cGMP RBD, is undergoing clinical study for inflammatory dermatoses (including psoriasis and atopic dermatitis).

XML 19 R9.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Liquidity and Going Concern

2. Liquidity and Going Concern

XML 20 R10.htm IDEA: XBRL DOCUMENT

Critical Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Critical Accounting Policies

3. Critical Accounting Policies

Recently Issued Accounting Standards

The CARES Act

XML 21 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Convertible Notes Payable

4. Convertible Notes Payable

2020 Financing

Since the 2020 Financing was launched and through June 30, 2020, the Company had received aggregate Loans of $2,575,000.

The Series D Preferred Stock

Convertible Notes Payable – Related Parties

Convertible Notes Payable – Non-Related Parties

Notes Payable

XML 22 R12.htm IDEA: XBRL DOCUMENT

Related Party Transactions

6 Months Ended

Jun. 30, 2020

Related Party Transactions

5. Related Party Transactions

See Note 4 and Note 6 for details of other related party transactions.

XML 23 R13.htm IDEA: XBRL DOCUMENT

Receivables

6 Months Ended

Jun. 30, 2020

Receivables [Abstract]

Receivables

6. Receivables

The following table summarizes the receivables at June 30, 2020 and December 31, 2019:

	June 30, 2020
	Tax Credit		Legal Fees			Settlement			Total

Provectus Australia Tax Credit	$	3,777	$	-		$	-		$	3,777
Gross receivable		-		455,500			1,649,043			2,104,543
Reserve for uncollectibility		-		(455,500	)		(1,649,043	)		(2,104,543	)
Net receivable	$	3,777	$	-		$	-		$	3,777

	December 31, 2019
	Tax Credit		Legal Fees			Settlement			Total

Provectus Australia Tax Credit	$	55,058	$	-		$	-		$	55,058
Gross receivable		-		455,500			1,649,043			2,104,543
Reserve for uncollectibility		-		(455,500	)		(1,649,043	)		(2,104,543	)
Net receivable	$	55,058	$	-		$	-		$	55,058

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Deficiency

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Stockholders' Deficiency

7. Stockholders’ Deficiency

Common Stock

XML 25 R15.htm IDEA: XBRL DOCUMENT

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

8. Leases

A summary of the Company’s right-of-use assets and liabilities is as follows:

	Six Months Ended June 30, 2020

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases	$	44,882

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	-

Weighted Average Remaining Lease Term
Operating leases		2.0 Years

Weighted Average Discount Rate
Operating leases		8.0	%

Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2020 were as follows:

Years	Amount

2020		45,784
2021		92,471
2022		46,687
Total future minimum lease payments		184,943
Less: amount representing imputed interest		(16,819	)
Total	$	168,123

XML 26 R16.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies and Litigation

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments, Contingencies and Litigation

9. Commitments, Contingencies and Litigation

Culpepper Travel Expenses and Related Collection Efforts

XML 27 R17.htm IDEA: XBRL DOCUMENT

Subsequent Events

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

10. Subsequent Events

Convertible Notes Payable

Exercise of Warrants

XML 28 R18.htm IDEA: XBRL DOCUMENT

Critical Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Recently Issued Accounting Standards

Recently Issued Accounting Standards

The CARES Act

XML 29 R19.htm IDEA: XBRL DOCUMENT

Receivables (Tables)

6 Months Ended

Jun. 30, 2020

Receivables [Abstract]

Summary of Receivables

The following table summarizes the receivables at June 30, 2020 and December 31, 2019:

	June 30, 2020
	Tax Credit		Legal Fees			Settlement			Total

Provectus Australia Tax Credit	$	3,777	$	-		$	-		$	3,777
Gross receivable		-		455,500			1,649,043			2,104,543
Reserve for uncollectibility		-		(455,500	)		(1,649,043	)		(2,104,543	)
Net receivable	$	3,777	$	-		$	-		$	3,777

	December 31, 2019
	Tax Credit		Legal Fees			Settlement			Total

Provectus Australia Tax Credit	$	55,058	$	-		$	-		$	55,058
Gross receivable		-		455,500			1,649,043			2,104,543
Reserve for uncollectibility		-		(455,500	)		(1,649,043	)		(2,104,543	)
Net receivable	$	55,058	$	-		$	-		$	55,058

XML 30 R20.htm IDEA: XBRL DOCUMENT

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Right-of-use Assets and Liabilities

A summary of the Company’s right-of-use assets and liabilities is as follows:

	Six Months Ended June 30, 2020

Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows used in operating leases	$	44,882

Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	-

Weighted Average Remaining Lease Term
Operating leases		2.0 Years

Weighted Average Discount Rate
Operating leases		8.0	%

Schedule of Future Minimum Payments Under Non-cancellable Lease

Future minimum payments under the Company’s non-cancellable lease obligations as of June 30, 2020 were as follows:

Years	Amount

2020		45,784
2021		92,471
2022		46,687
Total future minimum lease payments		184,943
Less: amount representing imputed interest		(16,819	)
Total	$	168,123

XML 31 R21.htm IDEA: XBRL DOCUMENT

Liquidity and Going Concern (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
	Apr. 20, 2020	Aug. 07, 2020	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Cash and cash equivalents			$ 1,483,214		$ 590,706
Proceeds from warrant exercise			42,640	$ 5,330
Subsequent Event [Member]
Proceeds from warrant exercise		$ 194,438
Subsequent Event [Member] \| 2020 Financing [Member]
Loans received in connection with financing		$ 450,000
Paycheck Protection Program [Member] \| The CARES Act [Member]
Loans received in connection with financing	$ 62,500		62,500
Economic Injury Disaster Loan [Member]
Loans received in connection with financing			$ 3,000

XML 32 R22.htm IDEA: XBRL DOCUMENT

Convertible Notes Payable (Details Narrative) - USD ($)		6 Months Ended
Convertible Notes Payable (Details Narrative) - USD ($)	Apr. 20, 2020	Jun. 30, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Borrowed outstanding convertible notes payable		$ 15,872,000	$ 500,000
Paycheck Protection Program [Member] \| The CARES Act [Member]
Related Party Transaction [Line Items]
Proceeds from loans	$ 62,500	62,500
Interest rate	1.00%
Debt instrument description	The PPP provides for loans to qualifying businesses for amounts of up to 2.5 times certain of the borrower's average monthly payroll expenses.
Debt instrument term	2 years
2020 Notes [Member] \| Non-Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount		2,375,000
Borrowed outstanding convertible notes payable		2,475,000
2020 Notes [Member] \| Related Party [Member]
Related Party Transaction [Line Items]
Debt principal amount		100,000
Borrowed outstanding convertible notes payable		100,000
2020 Financing [Member]
Related Party Transaction [Line Items]
Proceeds from loans		$ 2,575,000
2020 Financing [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Financing arrangement amount			$ 20,000,000
2017 and 2020 Financings [Member]
Related Party Transaction [Line Items]
Interest rate		8.00%

XML 33 R23.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - Mr Bruce Horowitz [Member] - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Consulting fees	$ 11,200	$ 61,200	$ 63,600	$ 171,200
Accrued director fees	$ 37,500	$ 37,500	$ 37,500	$ 37,500

XML 34 R24.htm IDEA: XBRL DOCUMENT

Receivables - Summary of Receivables (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Tax credit	$ 3,777	$ 55,058
Gross receivable	2,104,543	2,104,543
Reserve for uncollectibility	(2,104,543)	(2,104,543)
Net receivable	3,777	55,058
Legal Fees [Member]
Tax credit
Gross receivable	455,500	455,500
Reserve for uncollectibility	(455,500)	(455,500)
Net receivable
Settlement [Member]
Tax credit
Gross receivable	1,649,043	1,649,043
Reserve for uncollectibility	(1,649,043)	(1,649,043)
Net receivable
Provectus Australia [Member]
Tax credit	3,777	55,058
Gross receivable
Reserve for uncollectibility
Net receivable	$ 3,777	$ 55,058

XML 35 R25.htm IDEA: XBRL DOCUMENT

Stockholders' Deficiency (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
Stockholders' Deficiency (Details Narrative) - USD ($)	Aug. 07, 2020	Jun. 30, 2020	Jun. 30, 2019
Class of Stock [Line Items]
Proceeds from warrant exercise		$ 42,640	$ 5,330
Subsequent Event [Member]
Class of Stock [Line Items]
Warrant to purchase common stock	3,648,000
Warrant exercise price	$ 0.0533
Proceeds from warrant exercise	$ 194,438
Warrant Holders [Member]
Class of Stock [Line Items]
Warrant to purchase common stock		800,000
Warrant exercise price		$ 0.0533
Aggregate cash proceeds		$ 42,640
Common stock issued		800,000
Consultant [Member]
Class of Stock [Line Items]
Number of restricted common stock issued		25,000
Number of restricted common stock issued, value		$ 1,150

XML 36 R26.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative)	3 Months Ended		6 Months Ended
Leases (Details Narrative)	Jun. 30, 2020 USD ($) ft²	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($) ft²	Jun. 30, 2019 USD ($)
Leases payments, per month			$ 44,882
Lease expense	$ 22,332	$ 22,329	43,634	$ 57,134
Research and Development Expense [Member]
Lease expense	14,888	14,886	29,090	38,089
General and Administrative Expense [Member]
Lease expense	$ 7,444	$ 7,443	$ 14,544	$ 19,045
Knoxville, Tennessee [Member]
Area of land \| ft²	4,500		4,500
Lease term	5 years		5 years
Lease expiration date			Jun. 30, 2022
Knoxville, Tennessee [Member] \| Minimum [Member]
Leases payments, per month			$ 7,300
Knoxville, Tennessee [Member] \| Maximum [Member]
Leases payments, per month			$ 7,800

XML 37 R27.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Right-of-use Assets and Liabilities (Details)	6 Months Ended
	Jun. 30, 2020 USD ($)
Leases [Abstract]
Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows used in operating leases	$ 44,882
Right-of-use assets obtained in exchange for lease obligations: Operating leases
Weighted Average Remaining Lease Term: Operating leases	2 years
Weighted Average Discount Rate: Operating leases	8.00%

XML 38 R28.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details)	Jun. 30, 2020 USD ($)
Leases [Abstract]
2020	$ 45,784
2021	92,471
2022	46,687
Total future minimum lease payments	184,943
Less: amount representing imputed interest	(16,819)
Total	$ 168,123

XML 39 R29.htm IDEA: XBRL DOCUMENT

Commitments, Contingencies and Litigation (Details Narrative) - Culpepper Employment Agreement [Member] - Peter Culpepper [Member] - USD ($)	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Damages sought to be receivable	$ 2,240,000
Litigation cost	227,750
Litigation reserve	$ 2,104,543	$ 2,104,543

XML 40 R30.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Aug. 07, 2020	Jun. 30, 2020	Jun. 30, 2019
Proceeds from warrant exercise		$ 42,640	$ 5,330
Subsequent Event [Member]
Warrant to purchase common stock	3,648,000
Warrant exercise price	$ 0.0533
Proceeds from warrant exercise	$ 194,438
Subsequent Event [Member] \| 2020 Financing [Member]
Proceeds from loans	$ 450,000

EXCEL 41 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( )UZ#%$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "=>@Q1YO7C$N\ K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)^VJ+*';B^))07!!\1:2V=U@\X=DI-VW-XV[740?P&-F?OGF M&YA.!:%\Q.?H T8RF*XF.[@D5-BP U$0 $D=T,I4YX3+S9V/5E)^QCT$J3[D M'J'E_!8LDM22),S *BQ$UG=:"151DH\GO%8+/GS&H<"T AS0HJ,$3=T Z^>) MX3@-'5P ,XPPVO1=0+T02_5/;.D .R6G9);4.([UN"JYO$,#;T^/+V7=RKA$ MTBG,OY(1= RX8>?)KZN[^^T#ZUO>\HJOJZ;=-C>BY>)Z_3Z[_O"["%NOS<[\ M8^.S8-_!K[OHOP!02P,$% @ G7H,49E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" "=>@Q1! $!W[8# 6#0 & 'AL+W=O$Z-@AL)]FQ/6.S2==MDWCM9#L[G5XH( ,30%02LO27,RL6,KBJVV+(*89$4-6T!SN M[!C/B(0FCVQ1<$I"'92EMNLX$SLC26[-I[IOS>=35LHTR>F:(U%F&>'O2YJR M_D3.6&[;_3>D)CI1>P5.C_:%^-'<$3@U)( MEM7!T,Z2O/HE;W4BC@*\\8D MPYP/P7@T8D KP[P]$0K,CVM;T22^92S/>)J M-*BI"YT;'0VS27+U&K>2P]T$XN3\&PM*>"L2D3Q$-[E,Y#M:Y=7R4&D>(!$3 M3L74EO T%6,'M?*R4G9/*$_0'!LH&U3W@+ITC8)_E/D0>#QS>&+,AHBC+O"/^!X3>8\K>>=T//9*^7HG\6SD!P6X[\&R5$C.=*2 MHQ.2=?XW-$J4*+R5>Y+1KM2;==:;AY\W_N/3%BU7#^OOB\W=PK]Y>ESYB[^V M%VAU[P\-L.,&=MP'UH?%PTD*BR:D;^A/^MZ%:U9RX,_#X_%H;,":-%@3HUBS MH!_?B\[4F<.Q,_AAH+AL*"[[4:PI3YC:62&"_=D)9%8ZK/K?OGPYLW"O&K8K MH^("P$(-=YN2J(O('+\CJ: &CNN&X]JHXY><:XI$!+" ?E'"C7DRJPT&V!UX MV,"%G=83G7[[L&!<)GF$MI+(4J":N-,+S8J_/COH1[(CM\9]R%:YI+PZ 56Z MB)',K'B&S&W)W#YDMTD*KNC#*XP8[_2",SKW+!^0((!SGH-(6 F:"%N_QEX? MPFU&TA0M2P&WA3BY!\Z(25Z:]@!N+1_W\OR;C/)(+;7?04'&R&=90?+N!)H% MSVU/W!H\[N7PVQB*+".06>8L4&OMV&S.AR.'91F4)EO)@I<+P%/U"7HHI9!0 MQ$ .NVJ#6GFLE55M^SKWKD?>Q!U=PJGSVH75>CWN:?:UD]6>?PO=W7636>Z' M:TI6Z_+8;-.?J;2_GF8RBYTZ>NRCRE.M8%V0"Q2P,I=5$=KT-D7_0I>Z=CN\ M^F*X(VH#")32'80ZPTMX5[PJPJN&9(6N8Y^9A*I87\;PX4*Y&@#W=XS)0T,] MH/D4FO\/4$L#!!0 ( )UZ#%&-LO#390< #&PO=V]R:W-H M965T&ULK5EM;^,V$OXKA+% >X"]YHM>-R] -FEQM[BV0=/> M?68DVA96$KTDE>SVU]]0=BS;I&B[MQ^/TJU6>]$L*@KTW= MZIO)RICUA_E<%RO1KD4+ORRD:KB!H5K.]5H)7O:3FGI.,4[F#:_:R>UU M_]VCNKV6G:FK5CPJI+NFX>K;1U'+UYL)F;Q]\7NU7!G[Q?SV>LV7XDF8/]>/ M"D;SG9:R:D2K*]DB)18WDSORX9XE=D(O\9]*O.J]9V1=>9;RLQW\J[R98&N1 MJ$5AK H._U[$O:AKJPGL^+)5.MFM:2?N/[]I_[EW'IQYYEKO_Q1;AV*KKY"U[O^BUZTLGJ"BTT8VV\E@05.UF__\ZW8C]B:0 M:&0"W4Z@YTY@VPFL=W1C6>_6 S?\]EK)5Z2L-&BS#_W>]+/!FZJU87PR"GZM M8)ZYO9=M"4$1)8(G+>NJY 8&'WG-VT*@)ZM8HQGZ\^D!_?CN']=S XO:J?-B MN\#'S0)T9(%/7?L>,3Q%%%/LF7X?GOX@"IA.['22'TZ?@ZL[?^G.7]KK8V/^ M=DJ)UJ [K<&Q#P&-;*>1]1JC,8UE4A\7=O\]>YV["Q,(IK$^9%]KAB+,8UROX')SL D:. ?TL"> M'N:;S\C$-3*A>1+C(RM=N3Q/,&%^*].=E6G0RI\@7]>[8"\ZU59Z5;5+2 1( M#0UEMNB:KNZ+0BD *8J*]_57+M"[E$R3-.EGODNB:6*/N1)Z+?K:7'_SN9NZ MR4 8RXZ<]4AE+(O\OF8[7[.@K[^MA0+CVR6X!I4?*5OB9W(QZV# ;8!\!F=N M?.(TSH^3R".61Q'&?I/SG:%N)E "FBA7L3D%OFJ>>YL Z49P:E_&P@> M8 J?<9K&3]%V^L'^0\;$V7$Q\@E&:9+CD>0B>TA*SH*6?U?\N:HK4XD@OI ! ML@@-^GY7%+*#+$!K_LU6;"C81O%2>/>!>MR+TY0>YZM/D- XRTCWQ M@60>L=@Y.$&#SBH1A[X.0$K"2.KQM95&O!T'KUG0K8O D;VA%O_=-!!%R$)%#MX>SOF#1[)&&,\ADQD0%,2AM-+7#@S%UT0 M3=(4>WP*6O8WXC;@,0D#LL=I>40KZFW]]^(L<0$R@\+A5&=7+$TB.E(VZ "C M]!P8]2"5SU;J0B7-29;'>^5K8ZY'DF$*PG3$X %4*3F%?0=%#9B0;&?%812\ MQ@?U7L!HMHH.3QHF63)"&.C>J^A)7#_MVWDG)[S2)=YZ: &%=Z9L+)(#+:!A M6O#K7LD^/XHN\+,<)\,<)P,M8CH0/-H&&:L:GWI^J\RQ!HSD@<)\>PY).,XRC'9(2(TX%-T!-L M0C9-96PG0F^Z:;*U.R_: JQ&/_;5(_?V'\.*+TFD[\PJZ, J:!Y\=7PRLOB\ MDG4IE/X!/8A%!5ZWQ;=@?W( ?18&_486>A++A^(CV*\*@_VFCGT8'"DJA MJV5KZ\$5(L/7E=86_?HF8V>T@0=[U+A!G[I6['K&O<"#*$3S#%:^M8*O$%\N ME5B"5CB67SK;M[:E9]W;(FSOVK9$V!2X[IDJO?W:X,Y>D%O?0=%A] <&Q<(, MRAXLV)@S0D_>(C\6?8#>:4JB:91N.DPLRZ<9?.SX>P3U=)N*N60,C$K=_KE' M+LO!5G^98@-G8RP[^=#=6T@SU;V.NX%#I#4_ML*EWW-&,[P,?WRR4$- MP"/PQ09VQ<+LZNZ@^VRKHK<;PUSF,Z,LI3%@K9,97EF6D22C8_8./(F%>=(& M;L>JN==TE[S,:&H;DIFSRS[1"*>4C+UFL8'IL',N*_9X0G] +W(D<:^VO U8 MGZ"W 3O?N]6T5\J_<+6L6@U<; $S\?L4=D)M;FDW R/7_47GLS1&-OWC2G P MW@K [PL))&([L'>GN[ORV_\!4$L#!!0 ( )UZ#%'Z_2S-<@, $D, 8 M >&PO=V]R:W-H965T&ULG9=1KZ(X%,>_2D/V82:9O5! MP(F:S/5FL[O))&;,[#YL]J'"49H+U&F+SLRGWU/@HB@BKC'2PCFGOS\][:FS MHY"O*@70Y'N>%6INI5KO/]JVBE/(F7H2>RCPR5;(G&GLRIVM]A)84CGEF>TZ M3F#GC!?68E;=6\G%3)0ZXP6L)%%EGC/YXQDR<9Q;U'J[\87O4FUNV(O9GNU@ M#?KK?B6Q9[=1$IY#H;@HB(3MW/I$/RZI;QPJB[\X'-59FQ@I&R%>3>>/9&XY MA@@RB+4)P?!R@"5DF8F$'-^:H%8[IG$\;[]%_ZT2CV(V3,%29'_S1*=S*[)( M EM69OJ+./X.C:")B1>+3%6_Y%C;!KY%XE)ID3?.2)#SHKZR[\V+.'.@MQS< MQL$=Z^ U#EXEM":K9+TPS18S*8Y$&FN,9AK5NZF\40TOS#2NM<2G'/WT8BF* M!"<%$H(M)3*>,(V=9Y:Q(@:R-H$5>;=B$@J=@N8QR]Z37\G7]0MY]\O[F:T1 MPH2RXV; YWI ]\: ?Y;%$_&<#\1U7*?'?3GL_@(QNE/C3J===QNEM_K=5K]; MQ?-OQ/L4QV5>9I7H!' EQ)Q5^85?^%;R/::L)JQ(R+:4!5>TUIU-'BM!F^T!I8+J?G/5L,>[Q:ZE]B[8J$T MI!-_,KF [C/TH]#SHGYNO^7V![E7N&)!2J3&-(]?/R"L) >6E="'6\<*SRB< M)\>A%ZSWK#J@DQ9T\ABH2G$]*,)*G0K)?T+2!US'G)RAN!.G^EPPCS#L8 ,.K!A"QL.PBY%GB/= MF$P(1V7"/:L.9=121@]0CDJ#Z&IVJ?/VN4 >9=KAGK;YN5)E/_/T"L2; M.B'U_?!R;^BQC*91-#VW[!!3YU29G,>9\22B-&['N WWUAYG-'F?Z1WTLZ)* M!]'7(#G"/INB>@#@BM%3&:/#=>S_;5%-T,[6 MX_-:F+[ M[)QG#MF?F=SQ0I$,MNCE/(7H+NMS:]W18E\=_39"XT&R:J9XU@=I#/#Y5@C] MUC&GR?;?P^(_4$L#!!0 ( )UZ#%&ZM ^H# 4 *03 8 >&PO=V]R M:W-H965T&ULK5AK<^(V%/TK&J8?DIDFUL.6[0PPDP!MT]E' M)FFZGQ6L@&=MBUH"TG_?*^,8L(67[NX7_.#<7SRFBZ6Q+[SQ<"46\DF:Y]5#"4]> MPY*DN2QTJ@I4RM?1X);"RD1.9998)VO%/33IH:B,. H#''4#K -H. M\$\$L#J G9O!KP/\K:/ K+>Q M>3(E_)M"G!E/5)% M\L$P9U669H( P]/!BXP'HQ&ZA5]7LE2V'[5Z.*Y$.LD M!NT=[NT]$1:ACZJPBPUFD'ZQ!$_[8_G/?$> M6-#X0-]]N*.]A'^NBVO$\*^(8HH=[9F<'4YBEYP?RS[[[NQ'9K!F4+"*CYW@ MJ_N[6*#9V\J.#GW3P^HWK'[%ZI]@?91:BG*^1*)(8"YO8)%:V2'F&CT[)EXQ MV;5N,^8Q]P-_Z&T..Z4+(Q1'C+9P4P>.XR#&^!@WZ^(H]0,>! WN2'G0* ]Z ME?\N"S TJX2+!&9QJHTU>"-=VG=+ 12QF4=B2WL51#IW> MD=[%,!+6Y48.QLBUI)^3;/;CR8YL(GB_K^/^-0>*1 25F);&9-56;G?R3&SU M.C7.<=A/>+XQDY]%-/U91+.:Z&BQ#(/#WCIV^:!Z(M^UIR$CWM"\E% I.:TF MW26,M%;NB0-T!2C2FNP.&.6,M[:+F0,6T=@_,=$)W3M >QVX+S92FTJS]2 M MC(2^,'!C)[]3/.U.',;:VYL#16(>X+9Z!YG?MG+F0%$2XQ/;.MG7281]0WRM M5NZ6.*=5NQ"!GY(_/B$ MZ'TU1_K+N3NATWDUT:=IMK9?BM8"] ##8*+R'/:;IZ4HW?. =UK5WIEK2'38 M<'R-.^/_+-CLF[!C#_9E'>FOZ[Y4AP\@_78#I=U"HD_K_ 4,@.WUT .-/J^- M-N"5+?ZN4,C5M69QXLR1N75[5**1)86 /^_*F7>'VR" MYF!N_!]02P,$% @ G7H,4442VO<* P "PD !@ !X;"]W;W)K7[8U5;:?U @!A,*X,'Q(.; MN$U88A?;;;=_S[639EUPHPE>$MLYYUS?DYOK#/>,/XB<$(D>JY**D95+N1G8 MMDAS4F%QR3:$PI,5XQ66,.5K6VPXP9DF5:7M.4YD5[B@UGBHUV[Y>,BVLBPH MN>5(;*L*\Z<)*=E^9+G68>&N6.=2+=CCX0:OR8+(^\TMAYG=JF1%1:@H&$6< MK$;6M3N8QPJO =\*LA='8Z0R63+VH"8?LI'EJ V1DJ12*6"X[7W(I/YR$HLE)$5WI;RCNW?DR:?4.FEK!3Z MBO8U-@9PNA6250T9=E 5M+[CQ\:'(P+HF E>0_"ZA. $P6\(_FLC! TA>&V$ ML"'HU.TZ=VW<#$L\'G*V1URA04T-M/N:#7X55-7)0G)X6@!/CJ>,9O#6289@ M)%A99%C"9"'A!N4@!6(K>%1!$>:J.G8$?6)"H+-[BK=9 =AS=('N%S-T]N9\ M:$O8DA*VTR;\I [OG0COHQM&92[0'+:1&?BS?G[4P[?!BM8/[^#'Q.L5_+BE ME\AWWB+/\1S#?J:OIKM7IG3^+_K\GZ._,,-OB\/7>OX)O0\T915Y+@;TXWHI M)(>/^V>/>M"J!UH].*'^&;J@JB53U=3,2#-5J]N-+]S(#1(G'-J[X]=A 'IN M'/LJ_V/@S #T@\!-HN@E<&X"AD'L!L^*+](-VW3#7C._R)SPSJ?4&'RF;#@? M]'@:M4&B7D^A>4)KI- Y."&GF7*.3;6F1?&G:U. M#4"HLZO$[13DS #T@]B+HJ23O D(<1TGZ:1O'W7WBO"U/E8%2MF6ROI;;E?; MD_M:'UB=]8D[F+J&]1F<]/7!_"Q?_R;<8+XNJ$ E64$HYS*&=\7KH[>>2+;1 M9\N223BI]#"'OQ7"%0">KQB3AXD*T/[_C/\ 4$L#!!0 ( )UZ#%$W)(UG M#@D %%" 8 >&PO=V]R:W-H965T&ULK9QK;^.X%8;_ MBF 4Z"ZP&8LW78(DP,2RU2TZN\$&T_U0](/&9F)A;"F5Y&3VWY>2-:8I'3'D MF%\27UZ^) \IG8<2Y9NWLOI:;SEOO&_[75'?SK9-\W(]G]?K+=]G]8?RA1?B MFZ>RVF>->%L]S^N7BF>;KM!^-\>^'\SW65[,[FZZSQZJNYORT.SR@C]47GW8 M[[/JKWN^*]]N9VCV_8,_\N=MTWXPO[MYR9[Y(V\^OSQ4XMW\Y++)][RH\[+P M*OYT._N(KE,6M@4ZQ;]S_E:?O?;:KGPIRZ_MFU\WMS._;1'?\7736F3BWRM? M\-VN=1+M^%]O.CO5V18\?_W=?=5U7G3F2U;S1;G[,]\TV]M9-/,V_"D[[)H_ MRK=_\+Y#K/5;E[NZ^^N]]5I_YJT/=5/N^\*B!?N\./[/OO6!."L@?. "N"^ MAP7H1 '2%R"F!6A?@)H68'T!9MJ'H"\0F-80]@6ZT9\?H]L-39(UV=U-5;YY M5:L6;NV+;GR[TF)$\J*=BH]-);[-1;GF;E$6&S&Q^,83K^IREV^R1KQY;,0_ M,>.:VBN?O,4V*YYY[>6%^*)^V-[\$1[B/>I+)IM[2U%NS9 ^96^?* I M/Q>Q.04(?P_0/=8:_O-0?/"(_XN'?>P#[5GHBW_**E$<319/C&M',5!\:5P[ M6'QU6=_3'VZ\,A3D-%=)YTO?MLEQ5K#DUAK46;/*[KEVS-;VN6S.P^: M.HY\$D<^2T<^*T<^Z>4^RAQ@ISG [.; +UZ]S405T%PX6K'.JLW[KW?(%\?* MZ_DX&V@2 \W20+,RT*1ZC1*SX!2S0!NS1;G?"[*HNP,SK^N#.$H/+^(3_HU7 MZ[SF;1YYRZHJ$SD%.A:T]A9S^'(?I?_AJ?^AN_YKYM-"6XU%'"[W4>(0G>(0 M6<=! +/75I&OX4-(ZVAQ&KS<1^ER?.IR?%&7=6H>( M]08V87=DE+@R6KHR6KDR2AT8J1-!+HZ0?G6D3@1=8NN-]%QL(DI,1$L3T&X;C58KB+)W4@/WD8+UMXC..L4B?T@BH<# NBB.!KJ M$E!'0\2&PP+J@J%N95AO^KZ?&D5)[TB/[U9+OMZ+C:))0S8,*"#M.C:2)J!4 MQ)0R' W#"DH#0+HR;T!JY*K&5ZX*D/VRP&IYV/N?CWPT/@N,1=/'KL1[9,_W M/[2TZ^MA:A_\<3?&.J3JU"N9$M:Q'M9_9''66Y['% ^G+J!!,9IHK>1LK.?L M2]95O3536CV*= +(1,-9/!5IB:Q8CZRVRR*]G07V.#!2NRPA$>LA4;U MP$-71HDKHZ4#(S7@$L:P'L9LED5Z*YL!<'7-VI71TH&1.@ 2ZK >ZMY?%O4& M ^X2.7V ";!NQ&<)I(NH4 XR"*P;\=G*L'WI^_6J(93TBO7T:KZ@Z(W8J*EC MZ(*E$)\ED+3K&$)#Z(*E$)^MS-N:&C5 #:Z$6JR'VH^;3=[>[\]VWD.6;ZY^ M+;Q%]I(WXKW!$@1+N,-ZN#-:@N QFV$_IM@/QN,'2DD8160T?J#4CT.*PN'X M34@QBL+A^!DW(#5R5>,JP1,[!$_P9#T&28HB.N1-0,8PF6 @(FF3N*?-WE(! M,C3B34 5A>$$SR(4$P% ?(3+1(4FA1$^A.B33%[4@ E=& MB2NCI0,C->!G&Q3T#&R#9'HKFP%PQ<2NC)8.C-0!D$Q,;"Y0@F$?7]_K\A : M74Y83$G'*2N!I0@%Q$>#LRTLA5+6RKRMJ5$#U*!*SB5ZSOVX7A_VAUVW,>PX MPQ?*#/^7F.$F1$$D%A('%S7)&)VN"/&'*7H!Z3#U_6@XAI .DX ,!]#15H65 M8<-2!Q6JXR )DCCFUQM9W!@I,9 TBUQOZ-!;VES2G:\IX%(^"1Z^+2& M(5=;&1P8J3O_)+!2/;#J<$E?U&;/GZL-$*Z,E@Z,U(!+X*9ZX+;!)0I *JKV,>#Q)I ,DSCX6444*9D!+7C$LRI'LS?QY3>0$UN?N3C882X#;TQV@=\MA'8Q4[@,79= M8<("2D8W+Q>PED0HB(97D!)0BR,<4(2'0 EKV\M=.$;#83-O0VKFJT97,B4U MNB'^XV2A][+*:.G 2'V*0?(LT_/L^Y3!QA=213H(,8N">'B/"M:" MJ2Z!M3ZEB(ZN/H-:.-6M+-J;FK5!#:TD5Z8G5R,X8! ^BJ8R%HR>$ &!U \Q M0G@86T"*HLBGA.%A:"%I>YV)#D=L9=Z U,A5C:L$8Z8'XXNQ@(UYDXJI-)IT M8QDC4Z<\)J&4Z:'T1S)Z;ZG>\F"CQX/&JB@.\$2#)>0R/>3:YF*]G<7IE4'; M+"=O>;"S1[?T7*G+M&S\W--$I@658*:%E'"F!3T'F;8_%@$E$>>M* B&AR*D M9.U-Z:DC4<(IT\.I3?9FXPN9P-H<4$%K0*0PBEE9=[6U*@!QZ#. MSQY@W_/JN?MM@EK,OD/1')\//GUZ^OV#C]U3_X//[]'U$@&?K]!U>OQU VE_ M_+&%3UDE4GGM[?B3J,K_$(H94!U_O^#XIBE?NL?GOY1-4^Z[EUN>;7C5"L3W M3V79?'_35G#Z%8F[_P-02P,$% @ G7H,4=9?(M(O!@ <1@ !@ !X M;"]W;W)K,.N)5*[NJ;R^9Q5XO%T@1RLEKUFCN&B09.O3Q1D^O@B)4; 2?W+VJ/;ND0GE3H@?YN&J/%T$ M!A&K6*&-"0J7!W;!JLI8 AS_=$87O4^CN'__8OVS#1Z"N:.*78CJ+U[JS>DB M6Z"2K>FNTM_%X^^L"R@V]@I1*?L7/;:R:;) Q4YI47?*@*#F37NE3UTB]A3 MCEN!= IDK!#-*(2=0F@#;9'9L#Y135: F_ M_?;^9*D!BC&X+#JWYZU;,N,V05]$HS<*78+[\E!_"2'T<9"7.,Z) MU^ ?N^8C"H,/B 0D<."Y>+4ZSCUPPCZMH;47SJ5UR-AG*6KT;"!^#B'ESL3<)9^3=LX'87:0%%7XBFX!5#38?:O#7WA9X8BCM66%NQT 1R@F'Q@ MBQ7RY#KKH\B\47QB8*_@L_G-)N#3(!IORZE01!)"W/G->V2Y%]E9+:3F_UID MIK5MH<_!_G2!S"?^"Z9&):$4@VJB M38DJ3N]X9FNM>/IRJ1)'(X2XQ++ MLR2<20P9@!(OT&O)MI27+\7AADBFBP>UF8]KV"&'29KFT0S(H?_CT+_/BD+L M3./;TF>32"!++6GI+.7.U.$6(CB,QF"G^5('STZT\31E89;'V1BM MU^?;&R4>6 G[:>FLRSEOH/28TKZ>CZ>4D^$X"B>[>BJ7Y#@@<]MD("?\$W8" MLK:CS:UAT:O&.=F A$OSJ2*#525;9SX@ME7,[HO-[T$>"8!J:0\X7V$!W MQ$]WAX&9 'PK0:9GV]O(V0@1?(S4MP/ASTQ67!EU^F12DEG1APR MI3^8L:))6%.Q. SGEF#@2.+GR+Z; /@'#M^!Z/S9691.Z%,R)#$,P%/P4\$H MBSWX!](D?M*\7*]9H4V.+Y\*.ZVA[[#MT2]/=-6R'X^ MMN>?_=O^W/S,GA:/WI_CXXOV]'LPTQ[&?Z$2FJ*"#Z8UF P^IM 19'N^W3YH ML;5'Q'=":U';VPV#KU5I!.#WM8#YJ'LP#OK_,JS^ U!+ P04 " "=>@Q1 MWIU=+5$' #X$ & 'AL+W=OQFDW6Y=3AJ>HYW?AP%]=$23V4UL6SX3JEZL-D$K,UE3J.?44. M;PH?2IWP&%:36 72N1PJ[60^G;Z=E-JXX?FIK%V'\U-?)VL<70<5Z[+487M! MUF_.AK-AMW!C5NO$"Y/STTJOZ);2[]5UP-.DMY*;DEPTWJE Q=EP,?MP\9KW MRX:OAC9Q[[?B3);>W_'#+_G9<,H!D:4LL06-/_=T2=:R(83Q9VMSV+OD@_N_ M.^L_2^[(9:DC77K[A\G3^FSXXU#E5.C:IAN_^41M/F_87N9ME'_5IMT[':JL MCLF7[6%$4!K7_-4/+0[_S8%Y>V N<3>.),HKG?3Y:? ;%7@WK/$/255.(SCC MN"BW*>"MP;ET?E%'K,2HOH25=N8OS5B-U-]UJ@,I7Z@O%059C$J[7%WH:"*O M7P>*Y)*\.ITDA,(&)UGK]J)Q.W_&[5OUV;NTCNHGEU/^^/P$*?1YS+L\+N8O M&ORU=F-U/!VI^70^?<'><8_+L=@[?L;>8S@ND;ZW)M<-DX##?OH,Q\_&:9<9 M;=4M%@FT35']<[&,*8!X_WHAHM=]1*\EHM?_[TJ]['8V5O^#Y\&SGO'@[W$5 MZZ@NC*_6&E]"[D>7:B?% XUKV^]&6EW;9]^<-((4JM,F3, M01S%!!522^,396OGK5]M$84<@16=>'M.]]"QRKB5,F59.\]1Z6JK2LI-QBB) M1N1*:**0O DT4INUMW9[Y#<.KPI=&KME?&*IK56EAT35%D<1A<6&M89OM5BDWW\?-T!HX*/ (+<2MM!;J+/35WV.V\NKKJ-X\'WW[U_ M^^[]B?KB,@'L0[]R#4!T"B8[\.X3&DMZLO;5A"HWKW#[ &7:H0"@ MHD()%,!B @(ZK X":N1JP(GJ Y^"Z5($7ZK*:L<% &*XJA7NJN^)>QA>Z1DF M@6,*G&32?0._5/(JFI4S!7@#?(.)=\V=JUU&(:$5\I'1 &YLG3/>A3:6__+) M.LMPF8H:C.CX)(:_P%+-@*KD?>:A7((_+6:$Z MJNBL)2_[K9U&((Q0YJ&X+C:_6E$#SXI>O^).O];ZGGE CMU50"!7QHGAD&,W M-=>1GVMD##82SK^H0:ZX#P+VA56V;Y=NC?XS50F)%:'8KU 'B7BC3E 8H MX0(B!+P:[-OD>A3>)VQ%C('^K UGO]PJ#DZ"8G0M)5('H6,#<>UKBT,$ _<8 M)QH( /LW\$3<"'X'RCO8JU9?H\..VD1Z=)\2A6<7-9L>_4V"YAU;T@'*Q&>N M**-R"5T]GG'GG+V'#RC0H(_K]J=+EK+/.F1K]:;IKF.(M;QD'6S;7ZD=Q),C M&@FD.O^&V:6)\!4G8:(0!%L=@VP!"6AL&=(;E6Y0ZBV7EAXJ2 )7YPF\',43?!F[V\7-[=&E_WHT5QO-U$*7 MPW')#IFNWQ4TDZ8A")(A-26PC!FFR%*O +<;?!W'^TI):#W!)@S?HM M41,2J">3F@]MB)ZG;5-"?P?+;O[9Y?8XUAUOQ9?!:B8H'D"0L6?WO5'VUN.# M-'7$!U*U XMP= Z_8A1'9X2%AZ,B, M,)^49ZO=BKO( 80SD5UAINYA&3R&Y;E@'I5E%TH+UDCM6CJ?1F5$P;!7+]'A MT[;#H:,&> 0:)8Q"Q.6;[#>.;CYKUXM:YFDF=SN20N?AJV&HG.S6$V<43SI" M/E-?:84^;/?&F),N"$%'IM>>+U04]$*9>N?MS,+B/C[T73/9^QI%9U_)-W=4 M,B0T'Z;]:O]9OVB^9G?;F_\3@$BM#'AAJ<#1Z?C=FR&F+?G.;AZ2K^3;=ND3 MOI3EYQIC, 7>@/?0R@&+>?SM[-:*C.^OHSOUN[ZTK9!*T-K)WQ;U]+MWI.VVZOQ8MR_ M^*+**O"+V?5E(TNZI_"O9NWP:398R55-QBMKA*/B:GRS^.']BM?'!3\KVOJ# M9\&>;*Q]X ]W^=5XSH!(4Q;8@L2_1_I 6K,AP/BMLSD>CN2-A\^]]1^C[_!E M(SU]L/H7E8?J:OQN+'(J9*O#%[O]B3I_WK"]S&H?_XIMMW8^%EGK@ZV[S4!0 M*Y/^RZW?OE28-_:\U4G,\G8CE?SD_8.Q^\/8_VSK]A[Q^NE$9] ME4R("?OIK5:Y3/R _VM'GDQ(+VPA?E1&FDQ)+>[QDD#&X,6_;S8^.-#I/R<0 MK09$JXAH]?^)_VECRZDX84_\LR(\UXTTNS__Z=UR\?V%%YGT55P:'PB;'Z5F M-T=;+2:K=^>3Y6(E9!!(!PWIF![:$QD2KTQ+7@0KE,E:%+XJC2I4)DT0 M$!&'J *,MMZ3GXK/TJ#H.:*"GAK4*'96..-@U\B:LS)ZL-_.:PW\:Y$IE(K6 M8D/"4$;>0U/X<-]F_*EHM=X)53<'[3>D30>]%HF0B0TR-TJHG/$*D' M"B,%9(VS>0N(T6=/(E,N:VL?0 [ <%+AG6\W_"(P6W+;;H*0&ZC@BP?+C=*< M(\#M R]S&^^R36/Y\M0*=@ MFZE8_Q2?VG=,@< M+(&K"$DF&Q6DGHJ/K6/@C,^K)U$GL2(6JV-N3T8'/J#W9(36D<-S;64,WJNW MR\F;^5RTV)LRLI8[-,SL 1IB0]=R\%@Z68O7'(;E_&*]7L>GQ<5WXK4G$G_' M4K'Z+B(_. 6;F/TXYGPRQRF%LW4\Y!8QM[7*Q)WYM07=/RHO/7/B$^/JC[F] M^_AI.&>/\,/-E]M[<9.%5+GQ$+%%0G&R1=%]Y;-]%W64L*UIE.\C%BH'Q(ST M=.RFXAZ5 "6)56>?!?:0'*.]RZB^LG14,JU?+?ZRFJS.WP$#<\QTP>1B0&RV MTD7@]$0N0Z*/94AJ;\4WS*[>S&,T45'/S3(HAM<+OBGA19^?Q5Q$&B\N#CV[ M?>0:.SX]E0]\EE&">N(!D+>MPRO0RMFVK$0#%50;3:)I-QKY!.,;!^G%<:S! M*!1;%,2Q!Z^1"]WF?1Z.<8K72!FF$.A8S@'K!?+)*FI*2(5C):1-&1;\/ M+S+K&NOX2 P1&F+EHC9X!I-(4!/\@7:8H9J.\G=G$21 MYPT()\^,'"T0QS:4-F#@PM@XD"Q+I6,D'01T<[!O,OJ0O XT;TPC7I2],[\/M\]TF-P'6#(W:/BHHM@54@8 M!WW&,<=X5=+CHN66B5P61]*F/ 3B"!_V%FB_BL/Y'.H+].NYLL76R0#'V, P M>L.-W,5T6W"]3"0;2>[WQ!%BH1%YVU4RRH!O!T-O'MG-KQ1'=];=>C\UJ$BN M3:MT?I0S9;@ $9&Z9H60^@PM$76P4:S+E;%H)TS=N/I"5'8+ KEGQ):&78C! MI]'.ML?1_EV$.PYR0(K6<3PF!]3$Z\F>ED.+VR-47WGGJ7XX>K$?BE/]\%F/ MGW"J$+=(LBY(L81[$ &*$*\8Q QZ' Q,4,Y3. 7.@ M2TS"=%G@!LC*]X*2&%:%"G:AD*R/("L8+VW3FN65T MS:.7#K;#,A]3G63%$U(0I7@J?JD4U^-!(#:D%;+J!WI7<;[#[=[;) L@%E*, MRW^<@].DGD;(YQ5QK"('XU<,ZXGZ$B_55V^-ZU13H-&AP4%]D&@I@JH)4@MI M,.2>=2L^+(KU?D\M>:+SN+7S]L-+2JYTFUSCIH5@5U9C>/+3E^YYLX,[-RJH MC+\L@/"V-2%=OX>WPX\7-^G.OE^>?OGX+%VI#'?# EOGT^_?C(5+OR:D#]"# M>(/?V!!L'1\K=$YRO #?%Q;2UGW@ X:?=*[_"U!+ P04 " "=>@Q1Q-GH MA%L& #F#@ &0 'AL+W=O(5>;,<.8,>;IV_F-8*17IH3(VG/56,=:OA\-0KE0EPL#5RN++POE* M1+SZY3#47@F9%E5F.!F-CH:5T+9W?IK&KOWYJ6NBT59=>PI-50F_N5#&K<]Z MX]YVX$8O5Y$'AN>GM5BJ6Q7OZFN/MV&'(G6E;-#.DE>+L]YL_/KB@.>G";]K MM0Y[S\2>S)W[R"]7\JPW8D+*J#(R@L#/O;I4QC 0:'QJ,7N=25ZX_[Q%?Y=\ MAR]S$=2E,W]H&5=GO5<]DFHA&A-OW/IGU?ISR'BE,R']IW6>.X7%L@G15>UB MO%?:YE_QT,9A;\&KT1<63-H%D\0[&THLWX@HSD^]6Y/GV4#CA^1J6@URVO*F MW$:/KQKKXOFEUU&7PM"L+%UCH[9+NG9&EUJ%TV&$!9XW+%NTBXPV^0+:$;UW M-JX"O;52RT5SI2Q9A\R,R@.M*%?"+L$PND3O*:N@ MEU8OX)>-*,S.L;IUK$_JH50UO@62.I3&!5"9LX0,8+X$2[.AJ\QP+S"W45@I MO QT9>F]\.4J)4ZB2N\Z5Y];45PX_-!W3'$R.GDWN[U(C^.3[[>A>-;079U" MOUTWN[WKEOWJ!LG\#Z-I'Q&0R>&D15=5[=U]&VV$J*-67%GD8I,^#.A#"K# M7U#W"'#B$4A(Z54(>7/B2@=J$HE!CDB@,:5 CT_H,.]E:83OK / 2F2!W!MQ M"X*FWVO7A"*#A1:-IM!>PP/D+((.MA+['W1T?I.0C+*28Z)!7<=F9R+E!_J& M@C(W1B(_(O:01%UCE\7/6<,Z#".[(()LC=A,6= \3]N]Q1 !&(7,\5V+KW3:V^0.':$>9'.<<=1G\7EB< M+#@TG?)@.V**O15F$U [ND5'4*4#8LY2HU%Q25 M3A;+!G+).[#6!DK9H&% MN0"#L&FD0!F?5;GGQ#5O63LS<^>T4SXB4XAE08=40>N5AGRQNA:?Q4?FK&W# MSAH#9E "2]"?K>:DX+)V=P&2.A=ADFS1B?76!6>?]0*I*W$*4[+X>N=@D\]\ MV(IXX]63 "#Z9>-]%G1U+TPCXK:\L[]Y=[(/R(=<(U5;5KPY>_WC\3XE-UWN M7YT3_Z+]L1/;2OJ<^.SF[2U:0:3?NA9SG,\G_>(:T[1DAS] Q.O4YE2NZ]TZ M;9'!1JR?X$%L*@68_2Z(J5S:=?R"+/A_E,PB\1"/"D,[]H5)Q!5X%Z]$G= 38Y ZYZ[0< M0I"/D.L[)(-'K5S2\<&((_/3;';=WTNZ)"R<7 9B%DRVP(V8Y1E'E[\!G?12 M650.HP_2\/.A<KX!PG-$ M)B#F"RP=#8X/>^3SK2J_1%>GF\S<1=R+TN,*%U'E>0*^+YR+VQ&PO=V]R:W-H965TIG4\3MU>3]1!54ZK:*']WN M.^K\.6=YN:N"_%>[M'=Y,5%Y&Z*KN\.PH#8V_>JG#H?1@?>+SQQ8=@>68G=2 M)%;>ZZBO+[W;*<^[(8TOQ%4Y#>.,Y: \1(^G!N?B]9VSC^2C65>D?G21@EKI MO<;J43XV2#\ M3(2?_2^ /"[J;*9&TK)GT@0+]:VQVN;&;K*_6G5/.=5K\NKTA*$Z^=,TBUM2 MMT[[0NFF\>Z1<(%]I;&&B^!P7OU$OE8/4OY?\:G?_^[])#$1N#:A%VGS:( 7>N;K3=(Z&K2K6!E,&A-86HJ.2S M046GM/?:;HB%J7*PRI6P%UENZK;FQ1?+Q72QD+_79@[.]%;.LI^V+X%*5JQA MA!63F=CK_PJA>M2N]JR'B$&\[#@ZV.@VAZ- 79 MG(ILO7\F$"&H30C.[Y658+[R06(\V*\>VO6_0%L,T %?;<7,PC"=!38^]FX> M(C7EF]EOACZ^ JP/M:Y=:W&@=]*M(Z@>B '(0'!15PI%9-$MPDPQ\/ V)RI" M)EB]ECR(@F$%&U(B<]0H8QB'DXL/0>6H#)-#00%%E6O0#"*+WWA=3Y7&AM9[ MW*L$[A!-;".G.L21?33<.*B89KP^IF9#5MS@?;H R1JF!2D4>D+W"^S9@T%D MW_ FV\&.2K<,0%(=M]ZUFZT"?=% 7].Q9K75!3I:3D8J<[/QM-&1E*1:RO?I M^<4YIWN"](&\0=KS ;JQE4I/3 *C.U(C_*S"X54VXCT=N4'HB)[9KOSL1$"N"G"S'P M.8IAJDSY J(@=HQ,.&HWDA@2M(7BT):ER0TGBVV%&6%@.IB-#X:M]I!%3XBW M:AN>$;JRE9$#'FOQ26U=!6H3X!)[8+H)$5YP-B>VD)S&X6AL2U)=>>Y;IAM MQ(4'GM *6449C'G_I6I@EK:P#[P93=556\3 \PJ&$01:'7%.O79NQAD"O10P MI3SGAL*D0&NKJ_V_:11!)@2M&ES#,LVE:HEUZFH,3TDZY^,6 MYJL;:*_4\DVY!Q+/OG@'TH9(YH.#7'5W\_&;!W6#9KY:K9XU?EXSXQ_:/E,] MW^61#:-$JL3$+T#OEU97IMQS%-8MJH="Z(LU]6AFEK;AKI&P#W:'D36DX2\!QKL#>"B^2_+ P M8=WZ0$PO4_ BQD[HZAR8=JP5T5F\;&"C6S"MX71.2WYI973"2,T6;[:YY!CO MZ.% .Z7 ;0" ?,]M!DAACAK8KH]E9E+72D"03=G2VGX]G#)BJ:08QG.DRLZI M/6F,E-PH[ %6GYJW.OER*ET4R@KA>,0!MR&$_0_]%(:-T^C;>&AX'*0")LADUIX$K9:+H,+%N U#N)Q)QE M/Y/*(<3%/IN1"'CKTHGT(39N1]K[D7# "5:(S%]5V=+&FJ;B^(DU!T.R+O%[ M33-4-"R RHY)3#@H/51MO_VYKA%V*'RWL09]4ZN-%)A]J59&AS[(':5U28Q5 MZO? =ABHQ_"]]4(Z'[WEU^0W\BT#%[PN>0F?24X;$_?6G[04(6T MKZC$T<7LXGRB?/I^D1;1-?+-8.UB=+5<L6T0( /D& 9 >&PO=V]R:W-H965TVO(@BD^98 M,!.J$B6]62M=,$M3O8E,J9%E/JD041+'HZA@7 ;3L5];ZNE8559PB4L-IBH* MIG=S%&H["7K!?N&&;W+K%J+IN&0;O$7[M5QJFD4M2L8+E(8K"1K7DV#6NY@/ M7+P/^,9Q:P[&X"I9*77G)A^S21 [02@PM0Z!T>,>%RB$ R(9OQK,H*5TB8?C M/?I[7SO5LF(&%TI\YYG-)\%9 !FN627LC=I^P*:>H<-+E3#^'[9U;)^"T\I8 M533)I*#@LGZRA\:'@X2S^)F$I$E(O.Z:R*N\9)9-QUIM0;MH0G,#7ZK/)G%< MNDVYM9K>ORVV[_'Z+RX6?LQ6QFJ: M_3S",VAY!IYG\"JF'L<:AG!$]F6EN=R S9%^&A&8S,#P!RCJG4"W$T ^8F?O M8]='+U11,KF#DO$,KG0(Q.[+E#K (/ZGJ=H.MI)TIB%,$M3 M79&ZC&N*I1@/Z8*=GE8)\S2NA/8HP)80X*1_VAW&>(,+>/"$U(R:MJS^@"6_@#:@P,8/O6U1 ?MJ$"]\4W7D&^5M'5G:E?;OCZK MV]G?\/I2N&)ZP^F<"UQ3:AR>#@/0=:.M)U:5OKE1F=0J_3"GNPFU"Z#W:T5U M-1-'T-YVTS]02P,$% @ G7H,4;@NGJ&P @ O 8 !D !X;"]W;W)K M&ULS57?;]HP$'[GKSA%>V@E1D(2H$6 !.U^:IT0 M[;:':0\F.<"J$S/;@79__?[/G]WY"ZCO53W>H-HX"$3 MN1Y[&V.V0]_7R08SICMRBSF=K*3*F"%3K7V]5P;'@ZXVQ#G\RVK(UWJ+YM)TKLOR:)>49 MYIK+'!2NQMZT.YS%-MX%?.:XUXT]V$R64MY;XUTZ]@(K" 4FQC(P6G9XA4)8 M(I+QO>+TZBLML+D_L+]VN5,N2Z;Q2HHO/#6;L7?A08HK5@BSD/NW6.73LWR) M%-H]85_&AI$'2:&-S"HP* ME(TF-KMQJ3HTB>.Y_5-NC:)33C@S66""?,>6 O7(-T1HW7Y2@6I-^!YIJ[S8(*RFH9WB^ M!F.=5>/P'W1LZ%@]A;>8 :H=UK4#EJ=P30'9$A5$7>OM7@Y;SX):=^P!KA2F MW, '7#,!KY&XJ1&-0&H\ W?2,-&:*[FC)BHT3 M;0L$9-* O(&H/!@-:7U8_ M9[?>**EU0R4=Q;U>NQ<$T&WWX\MV$$<0MKM!W.[%46M15H*R5E#D]%Z[QEUR MPX*343/ >>LC3;'&A<>4_5*8?U8)TACT+AH7EH[_HA9'M,'O MVL%O3)0,U=K-30V)+')3#I?:6X_F:3F1GL++N7[#U)KG&@2N"!IT!CT/5#DK M2\/(K9M/2VEHVKGMACXOJ&P G:^D- ?#7E!_L"8_ 5!+ P04 " "=>@Q1 M?OQU;28# X!P &0 'AL+W=OZ0D4[6VU*[FAJ MLMA6!GD:0&41)XP=Q267*EHOP]J562]U[0JI\,J K*>)94E*BNU H/;570R>7,Z\_;!X*O$Q@[&X"/9 M:'WC)Y?I*F)>$!8HG&?@]+O#,RP*3T0R;CO.J'?I@5VXS[IYCUT\<\\G=&'#%YK6-IE'(&KK=-F!24$I5?OG]UT> M!H %>P*0=( DZ&X=!97GW/'UTN@&C+>XE4*B$KME[(C=V\2B8SIMF9(GF([@HU8NMW"A4DP?XF-2U4M+ M]M).DV<)/]1J#%,V@H0E[!F^:1_J-/!-G^"[N*VEV\'WDXUUAD[#CV M*''8)VYTT'!CN'+0,0/>HQ'2DF&W8\%IJ&HCP.FJ9)G!C#L$O84%8R/& M&-B<&[1^1;1";!#"G4?L.:$R4@38(1NS^70*%9J# !W#I2*H4MU];*3+O7X" M[=%V% *B0"NN=G3G!=*530=Z!+3U;#2;+D#^&1WO<[^/D-PAPB=- MP F#4.3)VZ&$BSOZDJI_J.]08Y>"QS5,YH]**,L24TF[Q0[NT#K"T(ZCXOGA MXWQQ'YFE/N=#:2-3P157 @]2[V3+I8$[7M1M\2>CR9P$-KD4.1TSZY.G,R5_ M$OO ]_AO5S >=+,2319ZMB4)M7)M8^M7^V?AI.V&O\W;-^4C-YE4%@K<$I2- MCZD+F[9/MQ.GJ] ;-]I1IPW#G)XV--Z ]K>:2M5-O(/^L5S_ E!+ P04 M" "=>@Q1F3T^K?8$ 4#0 &0 'AL+W=OM7#-RT: '%EF39EK.) 2?;13]VT2!)NRB*'FAI9!$KD2I) MQR1D$KN505,_2JUB-=*V29 U7E* J"Z:AB7 P6YV[N6BW.96-*+O!:@6ZJ MBJF'2RSEYF(0#G83-WQ=&#LQ6IS7;(VW:'ZMKQ6]C7HK&:]0:"X%*,PO!LOP M[#*V^]V&WSAN]-X8K":L*R27]/G(D"T[,TH[W&6+BU[ 3>&#%*;0\+W(,#O$ MCXA#3R3:$;F,7C7X4R.&, Y\B((H>,7>N'=L[.R-7W4,_EBNM%$4^S]?L1GW M-F-G,_[/8KV*LQ?K3-[ N%*5C43#Q1RI5"8\@'* M=C'V)T% R=HPA9!3F#V90RI5+14S"#+/>8K@K ,7\+.0VWM>ENC#'0J!6B." M*91LU@4P 72;"%CZ$F, M=P7TJ,/C,TWW92>"_F13SVI^/X0 I2)I@'GR$%:3AY MDA@=T/O26GB/6KR<%I.9'S[18ISX03+_'"U(Q'CR?U^2I;8S!V'VG:%=\2Q8 M!D)VE=,S!3.P02J;:P-55?;6)S* M_+2A4D".(%5<>UK)V8J7Q(04Y=IZELN2FBQ]YMU2/NQ_GP]=\ZZ8+J!FY),K M^I5L;!7O4X"WX:G(AT;UD6@S;^_0,^^7WOO46LSMX=#HUL23G*4,A-B6H4C\?(A)!?P[O&D$:V,^-54Y&H MW2>Q(=G5<^'TA!2G*:4)-:)L5>*Q@S:23[.QS>/]$#O2L'2Q\]R6>.+/DMB. M0YA'?CP+[3B">.I/DYG75I+\D&][>,\Z3&)_3@7_/?4-9UUB4"EP38MPSO.J M;HP+$W4*J U\&TY]2F3XKCO@!,)IXH?1&)YKN$9[G6J%:NWZ<0U.Y[9I[6?[ MEG_9=KJ/V]O_"Q^86G-2J\2&PO M=V]R:W-H965T[!N9>\ M.AK[A]L3>?&UT*6[GNR]KU[-YR[;4R'=S%14XLG6V$)Z7-K=W%669!XV%7J> M+A8OYH54Y>3F*MS[:&^N3.VU*NFC%:XN"FGO;TF;X_5D.6EO?%*[O><;\YNK M2N[H,_E_5!\MKN:=E5P55#IE2F%I>SU9+U_=KGA]6/!/14%,UF1%"H,OZ57QL< M!ALN%]_8D#8;TA!W=!2B?".]O+FRYB@LKX8U_A%2#;L1G"JY*)^]Q5.%??[F MSA2%\D#9NZFX,Z57Y8[*3)$3LLS%;\JKG63\KN8>[GC3/&M,WT;3Z3=,OQ#O M86_OQ-LRIWR\?XXPNUC3-M;;]$F#O];E3)PMIB)=I(LG[)UUN9\%>V??SSTD M.T[_C7*9-JZV)/Z]WCAO0:#_/.%UU7E=!:^K_P?B3YM^.1//MB[N:EU159$5 M7ZP\D!9OO^*DNV;A)]+2$V.BFP.4O-U" P#5AU*\H8R*#;:F%UR-Y8MIXO_7*;IXG6_)MQ8OOY)U*4L56%JI^_%P;!7 M;X0G"[HCAFA5E;BA"G&W5[1%J)35?)S%A^U6962#__+G^/0#DI*<>/P#5BD[M=\),^/.UA^;"+N[K0!3P5MMQ3D1*BBH%PA3'T_3;;6%$)J M+2KC%&/F!!+?D\YQJOV>,^$"5;*\#Q&1S/:,E *JKMXX!4L6I9JV8"%DD: M^%5Y0-0M3S-3YG7&*2"LD%Z=*]\0W1.UNP;DL[3#'Q @445E#6=!D=QXI(I- M;1W%8X]DNXAGXLL@38]&$NRVM<2%].!J#FNXGP3(6^<]7(^E/1T\5]AS1#*E M$8X.("K7L9+WC0SAOP8.-KW'ZO8@< @]+9) BY85V!:BX[7L 6T)TL#5?$9T M,_&NMEAF"V/I)%1$J0T4Q#)!E-?-V43ZZ:NER, 8-P5JU!*^8I;?":C2M4M&\K"\>.T$4PY*B8*Q M?+F]M!U)M1KPVODV>PGU*T/%?T@AJ1?G:'*:G!L^#&F$PU))E7/)66,;(4[. MEHT0<]4&HB3RF@+LH)C<:!J3W'$6@Z..>GN((5MN)AN.\%=9UAC8V/X%J^@ MS"8V\ %8N@<"Q['$#(%)Q@G!9-J05Y, -$HB(FM&& M_J@]9&8R/"KT-=-UWJ \X)?TZ,@EW;N&K6)+Q."'2()@4(D29^W.D1I^ MFB;(7M,HWE!K.,BZ,2+: C%B3+-!PDU]\Z2E^E'V\H?@3IMBJWX]*-^K/D:7 M4,:F=6%X.3WP [XE3_&MP01QRE[E3^D_T!4)/@@A="-V8[%Z[O>2=SQ7B_:PWT\AJV?Z^? ML]%(K).3E#_[& THS83!J:I\/.;+-+#F,J+=HL!1.9 \#]T:?9=E\M]H4O0<:?L!DS#97CT[Z?B"Y4EI)98HWEZVBH,!<.(P]LP1Q@/1%3W)#T+H;RP_O:&.;!M*Z&%0UYIH4)@Y9)AY!N$$AJ>7(*)K.Q7_K?-<= M[/?20GK3](DLZBK,XH]BD3Q5K3CP(;CND'A8O8)(?0K>*M5B-/@)!;)A,]J]CQC'/) MT"EB=CQ*G;;*7NQCV>#[8=E*1D5#[5KNA2&V1MLN!E'V%>3S5G%#<2D7YTSYFCWT9F0^^2Z&K[,+7-QX&(%3Q$U5WM_O MX[? MM?KE\>L@3O<._0!3\19;%[.+\XFP\8M;O/"F"E^Y-@833A%^[DE"JG@!GF^- M\>T%.^@^>][\#U!+ P04 " "=>@Q1![=R_;L" 6!@ &0 'AL+W=O MW#@ E;!IK9IFG^_LR&,J6LT:2]@G[_[[KO#=RSV2C^: M'"2U5* MLPP*:^O+,#1I@14W$U6CI).=TA6WM-5Y:&J-//-.51E&C)V'%1:-J%/4LF*I1& M* D:=\O@:GJY3AS> [X+W)O!&EPF6Z4>W>9SM@R8$X0EIM8Q<'H]XS66I2,B M&4\=9]"'=([#]9']H\^=J?!"9+9;!/( ,=[PI[9W:?\(NGYGC2U5I M_!/V+3:Z""!MC%55YTP**B';-W_IZC!PF+,W'*+.(?*ZVT!>Y0=N^6JAU1ZT M0Q.;6_A4O3>)$])]E'NKZ520GUW=-UN#3PU*"S?/]#2+T!*M.PS3CF+=4D1O M4)S#K9*V,' C,\S^] ])3J\I.FI:1R<)OS1R C$;0\0B=H(O[G.,/5_\KSG" MCZNML9INQ,\3]$E/GWCZY']*>)IBRB;P6N6UDL^HK=B6"%^513/:\ -WNP'6 M*J!Z85^O,=@"R;6JN3P (5!C-A*2<-P#/!7=,EN002KY3F/)+69084>1'0^,\ZH;G1;4A\#E0"5%BB4FX*J MI%+$S <]FUXDXR2>3_YVN<)!KU:H#LQ;[G. MA310XHY3]+ #=3J%V8U7M.W^K+,T1ORQH<*-V #K?*;H*W<8%Z'\%JU]0 M2P,$% @ G7H,43 ,+V@#!@ Y T !D !X;"]W;W)K&ULI5?;;ALW$'W?KQBH0)$ JFZ^I8EM0':2U@72&G;X93$=EKTP=9>.&?.#&?.<$_7SG\*2Z4BW5?&AK/>,L;Z M]7 8RJ6J1!BX6EF\F3M?B8A;OQB&VBLADU%EAI/1Z'A8"6U[YZ?IV;4_/W5- M--JJ:T^AJ2KA-Q?*N/59;]S;/KC1BV7D!\/STUHLU*V*=_6UQ]VP0Y&Z4C9H M9\FK^5EO.GY]<*;*WG6&S$A9509&4'@9Z4NE3$, M!!J?6\Q>YY(-]Z^WZ.]3[(AE)H*Z=.8/+>/RK/>J1U+-16/BC5O_K-IXCABO M=":D_[3.:P]'/2J;$%W5&H-!I6W^%?=M'O8,7CUE,&D-)HEW=I18OA51G)]Z MMR;/JX'&%RG49 URVO*FW$:/MQIV\?S2ZZA+86A:EJZQ4=L%73NC2ZT"O=A> MO3P=1CACDV'9 E]DX,D3P,?TP=FX#/3.2B4?V@]!LF,ZV3*]F#P+^$MC!W0P MZM-D-!D]@W?017Z0\ Z>P'LLX#^GLQ ]*N6O9QP<=@X.DX/#)QSE*TL?A"^7*5=]BDM%[[45MM0/=[JS*"XWG5FO[I!HL M=>)557NW4FCM&"BZ';7BRB+]37HQH(]+Y14)_ 6U4C;S""2D]"H$,-(6D>E M32(QR!D)-";F,!Z_H2-:,T1IA.^\ \!**O?X!')S@J*MM&M"D<%"BT8'4![# M#\A9)!ULI:I=T-'Y34(RRDK.B09U'9N=B\CTH9H*NM082=9%FB&>ND:QB9E1 M#,8[<^FJ6MA-Z[$XIK4 PD/6\ ['47E( 'MCNQ+]Q;7:8$_Y#8J&P_V*H5FJ AQLL+--S3-" MNCJG>UXPG0>5A5H @JN NX-@4G,=6$$W2OB )0MM4]!BCEVAM^C7:H:+\1%+ MU_C'KDZ/$ZV3%G0/$_Y7&)# *&3.YU)LH]OF-K_@%.THD^.:HZZ"/PB+NP2Y#4N0D9%$V!B:X\LVM#//NY!A0 M#[E'JK:M>'/$3I8?[E,*$T%Q#KH@Z-\%L>VDKXE/;][=8A1$^JT;,2=Y)/>+ M:RS3D@/^"!&O*>B%5;FO=W;:HH*-6'^!![&I'&+()019]/LAF$$2)081'.L^' M2L4E>!6L1Y\Q$>"3)^1NTG(*03Y"KN]0#!Z]=):#;]XHLMWQ?,G3[JW'!@ZUDH M%9\3VYHZ&.>::A5^3^(>(N^5Q7YW%_^]N[_=&(/'CH3#O9-WI?PB?5\P+%HR M'\*[I]TGS#2?W'?+\_QC#'NP( ,$& 9 M >&PO=V]R:W-H965T9>VENVM(^NL[NS:.HP;40P\]X-W9G??FS> 9 MCW92W>L,TO''>ZM0>;R5+*>VM\2,=>8 6A MP,18!D;+%J]1"$M$,G[6G%X3T@+;^SW[6Y<[Y;)D&J^E^,93DXV]"P]27+%2 MF+G,/$A*;61>@TE!SHMJ90]U'5J B^ (*P!H=-= M!7(J;YAADY&2.U#6F]CLQJ7JT"2.%_9/N3.*;CGAS&2."?(M6PK4<+)PZ^G( M-\1L[_VD9KFJ6,(#+.=P*PN3:7A3I)@^Q_NDJ)$5[F5=A4<)/Y;%&41!%\(@ M#([P14V:D>.+_B+-[].E-HI>AQ]'B..&.';$\0'BN^IE!KF"5HR7*GB4Q_;> M4&]8@F./FDNCVJ(W660(*RFH<7BQ!F.IZ^[AOR@10]?J*6B'&:"Z85,W8$4* M-^20+U%!U+.GOX%IAR@U\PC43\!:)F[K1"*3N,["0AHG.3,DM M=5*I85K:\@G.H 5]!5%W,!C0^KK^.;OS3DFM6RKI*N[WN_T@@%[W/+[L!G$$ M8;<7Q-U^''7F5>J4M8*RH)?;=>^2"VX>"7JRQY["R1.G*OAOLM4VM>:!"X(FAP-NA[H*J!61E&;MR06DI#(\]M,_K&H+(.=+^2TNP- M&Z#Y:DU^ U!+ P04 " "=>@Q1UTM0;WH# #Q!P &0 'AL+W=OT42E?,TE1O(E-K9+EWJD04#X>3J&)CV<69L_<&?W+*G$5Y[;18L$;86[7]%;MXO,!, M">._L&UM)TD(66.LJCIG4E!QV?[98Y>'/8=T^(9#W#G$7G=+Y%5^9)8MYUIM M03MK0G,#'ZKW)G%W[.U0/-A'ED"=5M1U@%D5Q3M%%_%1P,^-/(7Q< #Q,!X>P1OW$8X]WOAX MA'^OUL9J*H)_CF F/6;B,9,W,._H;N2-0% %^#H^4<5)8Q!6QJ UP&0.5YRM MN>"6HWDMJ\<)5KM;XAALB7"IJIK)IY]^2./1]&<#>H\U8,^LXID5."T9*)2@ MFV=FP1U_/#@KH$QCG^G@DID2:L9S\M# *M5(PN0R$XTSYM+KJ"B;C4:ZEM9) M$RZY^Z2SX(\:-;-<;B!SB(4C!U+I(52_*=IC>0=),DC3.#A(8Q>06EMJ*ZTG M/F8EDQOTZEI:M19\P]SE/J#MD4^"K_Y2$L#J@7;)^19=HW)6OBS@'G7UTC4^ M'<)?R+1Y"?"1F\QE!FZ9Q9>>*7G^>*3 SOH"._O?!?:IL91QN";=55/!#7MR MV3?PA0Y1P^]*GF1,9M37W!5NXWJMX(X2NMX_,S7+H'S!<=LQ5QUSO MF!O/_$I9!O(_:EX+&(SB/!\ET MY,8Q))/!))T&]\HR <6AWI:\5SU*D\%Y,@ZNT)A95^#TKOAPI3]$7M6-]>5F M29&Q\'XT&:2C<_C0$;R#T20=C.(QO';&T5X;KE!O_&-CP-=+VY'[U?X]6[5M M_-F\?0ROF=YPRI; @ER'IU,Z/=T^,.W$JMHW];6R]$3X84EO,FIG0/N%4G8W M<03]*[_\#E!+ P04 " "=>@Q1;M<_32X# X"@ &0 'AL+W=O8$]GA*V3ZSH*+G"@]%4M;K@22I 3EF>TY3F3GA#)K-"BOW8K1 M@!S18D27.4-VO;H6>V35+0G-D MDG(& A=#Z]Q]<^F6@'+%)XH;V1B#267.^8.97"5#RS&*,,-8&0JB3VL<8Y89 M)JWC>T5JU3$-L#E^8K\LD]?)S(G$,<\^TT2E0ZMG08(+4F3JCF_>8950:/AB MGLGR")O=VLBS("ZDXGD%U@IRRG9G\E@9T0"XP0& 5P&\4P%^!?!/!005(#@5 M$%: \%1 5 &BTON=6:73$Z+(:"#X!H19K=G,H"Q7B=8&4V9VUDP)?9=JG!I= MT^\%3:C: F$)O.64+6',68R"P=D$%:&9A ]$"&)VP$MX#?>S"9R]>#FPE0YO M2.RX"G6Q"^4="'6^$AWPG%?Z[SDM\/$?X,6R T[W('QR'/Z^8!WP#T>?G@QW M^RWPR^/P"<8:[K;!;5VQNFQ>73:OY L.\(V)3,N*Q6: NH9KDB%3LLV8'554 M4IDWS7KD!CW?M'P1^KSW'J-81_5V.\*-\-N"2,L)B\R(X(?MN M';5[-.HU)TSJ5A2C?HTD0!G$G+&JO6RH2F'Q%+;-BNZ>%4'HZ%^[%;U:5.]X M2"Y$U7/J8(X_.[Z0S.XY.V1+^.W_^/IEST]TR)O-#Y M[3F9]/>>IN>KGBEWG5]]PSFJ?:JE\IS&<,6^%6(+$RJ)5"C )'6*26ZC1;G_ MT:9)Q=[TR=_?.G:CAYIOJALBEE2'S7"A84ZGJQT4N\^4W43Q5=E6YUSI)ET. M4_UIA\(LT/<77.^I:F(Z=?VQ./H)4$L#!!0 ( )UZ#%'X=71?.P0 +\0 M 9 >&PO=V]R:W-H965TX[T:*OTHUES;N$IB:6Y;*VM33\$@8G6/&&FK5(N\MDCKQQ?W8K6V M[HM@/$K9BC]P^SF=:1P%E96%2+@T0DG0?'G9NB(?IK3O /F,OP7?FL8SN*7, ME7IT@YO%92MT$?&81]:98/BQX1,>Q\X2QO&M--JJ?#I@\_F']8_YXG$QZ^V?_!R03UG+U*QR?_#MIC;IRV(,F-54H(Q@D3( MXI,]E40T ,/P"("6 /H3@'2/ #HEH',JH%L"NCDSQ5)R'J;,LO%(JRUH-QNM MN8>+H*M5MH.$[_*/A ?C$#_\SDVWH M'(=/_? ICQ!.')Q<[,,#9*RBC5:TT=Q>YXB]>QXSRQ=(EK8[^*29-*S8R%_^ MPJEP8WEBOGH<=2I'G=Q1]XBC:Z41@9ZP9HUEM+1(VB%>"_O] MW+Y3@5 M9@E\N>7)G.NO\"]\6G.87-W__@!7D:U>> CL5?Y[Y\U4OW+4]R]4JXCSA8&E M5@G$"AT=JI+^,Y;[M/=S+B;%K-[167L1#JH(!]X(;Z3EFAL+6,Z'MLJU'T[: M8?BKAZAA%<;0:V?*YQ:$-%9GV$ LJK2)M$A=3@X%Y3?F]LUL-H-4JXU 2X"M ML" ?K()O&8O%UAYZ)BY^)5[&#*DD.T^*U0 MV'&FC2<>$M8=(O3;0L4M>T.C8.^4?+]?6R<4+6FT)7+>LB6UE!/Z,N.I%C(2 M*8O+G7&P0]%G54D[@]Y1B22UR)-SJWSI8"^VKB^V6K^)7\ /I__UJ:\%FYQ9 ML4DMV<2OV:>G_KD@$T]S)+4D$[^H_@^9'[PNM%JFB5]:\\1_%)(A.QC4*3FN M18YOT_KRI+32;,RTYRD@6DL9)?^%1RRB6_8DDBPYA5K:.)F> M^6A*:]FB?MFJ%^6N"'+%\XYUM(JF]/D1DX:A9[/26J7H2RI%!H#E _MLFY.X MK:6)GEF::"U-U"]-+QW6)B_@A\=.:T'CLNBN]K=,K_"\ 3%?HJ&P/4 *='%; M+@96I?G]<:XLWD;SQS5G"Z[=!'R_5"A1Y@Q1!D3?K(@" Y!P &0 'AL+W=O-M<0NMK-N_'JNG31T M:UHJ>$G\<<^Y]UPGQ_%:R =5 &CR5)5<#9U"Z]6EZZJL@(JJ,[$"CCL+(2NJ M<2J7KEI)H+D%5:4;>-[ K2CC3A+;M9E,8E'KDG&82:+JJJ+R>02E6 \=W]DL MW+)EHKF<29V['DK *NF.!$PF+H7/F7D\C$VX"O#-9J:TR, MDKD0#V;R*1\ZGBD(2LBT8:#X>H0QE*4APC)^MIQ.E]( M\<;]H]6.VJ94P5C M47YCN2Z&SGN'Y+"@=:EOQ?H:6CWGAB\3I;)/LFYC/8=DM=*B:L%80<5X\Z9/ M;1^V ,C3#PA:0/ :$.T!A"T@/#9#U *B8S.)T<@LEU9"3&97ZF7R1E"MJCU"1DQ0T9:4BGZF4 MU)SG*7E'II*,9)T!N1:8BNE?Y/L4JCG('[AY?Y>2DS>GL:NQ-)/ S=HR1DT9 MP9XR0C(57!>*3'@.>0\^/8P?',"[6&?7EV#3EU%PD/"FYF6+]O"-\7/ 'X_Q)5D J+[C;0@&EL!XTV/B M^^A5L?NXW;3=J,%N5-H3%0Y>1TUZ,EZ\('LA->JD1@>E7F69K/%_R)E$*Q-R MK^!H)WUX<;XC^*BH]*BHR=^B&KWNEA=4()?6A!7)1,UU<^+=:N?S5];>7JV/ M_,NQW[.>XKW0V/@?^N92F5*Y9&@<)2PPE7=V@58E&Z-N)EJLK!/-A49?L\," M[S:0)@#W%T+HS<0DZ&[+Y#=02P,$% @ G7H,40,,-NQ@ P 1Q !D M !X;"]W;W)K&ULK5A=;YLP%/TK%MI#*VT%$\A' ME43JA[H/K5/4KMO#M >'W"16#0Z"=S+F*B]% L7+D20&8I*&:N[WE= M-R8T<<;#]-Y$C(=\K1A-8"*07,&.ARNR@'M0 M#ZN)T".W8)G1&!))>8($S$?.!3Z_\CT#2"-^4=C*G6MD4IER_F@&7V@=F/;DE#*JGIOD!C49 MGYKU'A!8$1P6@D.KX!_Z=6A?T; VG<+;5VKMN^P( S=@&ZS/[<0 M3T'\M>SN7L'::[&[K5AC'.=R12(8.=H9TE([8]34L>UY*LGUB^3ZK5ND7ZM5 M$.IJ>:]*NC>L(G!0"!R\:X,,ZON^4>W^N(I<[)4FX+5L$#O!$7OF'8BJ2>XX M';8FJ3])% /]":(.Z31<&@ENXR1V\#$+UYZHFF#I2+B])>&ZU^!N,/!J[_@# M JLR2U?"[VM+N,%NWM!\0&15=.E,N*TUV0F.V4#MB:I)EA:'[1XW$7RC:[&6 MZ$)_T0K"*#FH!4NWPVWL+@?O&*(N]X]*L<'NWLE,<4^/V1-4T2\O#[^MY M=KIC4FY/5#U E*[IMW7-G&#?.:(>U;3SW)U3GCEBWQ*QH(E$#.8:YYWU]-85 MV:DU&RB^2@]^4Z[T,3*]7.J3/@@3H)_/.5&PO=V]R:W-H965TD[/3O MEZ1D24DDU062%UND>,Z<&4Y.QO,3X_4Y8C#?F%=X0\;/-, M<^(KA9-H/2.=RHZQ>[WX'"TL1RN"%$*I*8CZ.L(:TE0S*1T_*U*KCJF![>97,C@A8L_0;C62RL*86BF!/BE3>LM,GJ!(*-%_(4F$^T:D\&P06"@LA M65:!E8*,YN4W>:@*T0+@/H!; =Q+ 5X%\)X"_!Z 7P%\4YDR%5.'#9%D.>?L MA+@^K=CT@RFF0:OT::[O?2NY>DL53BZWDH7W"4LCX.(-VL">AA3R\!=ZNP%) M:"K0%\(YT9?S#OV-[K8;]/:O=W-;JMB:P0ZK.*LRCML3!Z-KELM$H(]Y!%$' M?CV,'P_@;95SG;A[3GSE#A)>%?$(.9/WR'5)OO^GWJ//$C+Q8X#=K]E]P^[WL-]P%@)$ NTY MR]!)-T0N$3P #ZF KN*5?&/#IZWGN/3=L:\*=6S7Z/FIP/.:0X^T!K768%#K MMM@)^%F $OCQJ#^_7T.V SY4AW'-/7Z%*D]J]LF@\F]5725#AX*'B7(S%+(L M4^XH=+RN/[J2,6A5T!O[4\?I*>*TEC*]2,KYBM&!T[#KHE]-N'=AI[-&YJ!*?2HN\I)MPRWOQ*_03=AM^]Z4[ M:EU1MEM*]U-?1^'&H;#W,CVUKH@N;2K]K&K..80$ZFJ0$2B!)1=UJGA M=P[V6$+C3GC8GM:M\B,J1-'SSS#XLUMH' R/?Q,_%VHD(I<9(VZ\"T]>HY4; M0\+#CO2ET%IU Y"JLZ1$#WJY:%B3I\5TPWZ:]F8%!YVJ4LUO4='DA;=K=[A M6SAXJLQNS7<9\-C,R4*%*G)93CSU;CV+7YD)],G^6L_H9FYL:,H!_YKPF.8" MI;!7E,YHHJK%RYFY7$AV,%/DCDDUDYK'1/W. *X/J/=[QN1YH0/4OUR6_P-0 M2P,$% @ G7H,40>H)!^I P O@T !D !X;"]W;W)K&ULK5?;;N,V$'W>?@6A%L4N$$2B;I92VT!LN>VV31$DW?:AZ -C MC6UA)5(EZ4N _?B2DBS;DJ*H35]LD9HY,^=PQ"''>\8_BPV 1(0$7'-$C6&ZDGS.DX)VMX!/DIO^=J9-8H<9(!%0FC MB,-J8MSBFP7VM4-A\7L">W'VC#25)\8^Z\''>&)8.B-(82DU!%%_.YA#FFHD ME<6VMT/1#H7[AK?1*J"Z41\G5VT3YR>DO MH%06Z'T$DB2I0+\2SHE>NP]C4RI\;64N*ZQ9B66_@.6@.T;E1J %C2'N\(_Z M_?T>?U/QJLG91W(SNQ?PIRV]1HYUA6S+MCX]1NC]-Q]6\MNO\2CXKB.]^6 T M'%9H723_UYP6;\WI0CBGK@JG@'7[JR(GSVI/D.(*YGBW")Y1=8>F/: M35TW".RQN>M(P:U3<%]/ <%![8@"NFK1;46U;<7J]/!] .'+#2(T1A'LU-:=:]'1HJ2._KR#[ GX M7SW+ZM>Q_+=IZK=TP&HE@X:FW59^0].VE1U:H=70M&WE!%80=FLZJGF.>GG^ M !0X20M);V.U:R9"EKO:OU$UJ*,%;U,U:-7-R'4;Q37O-'(:FK:-L.LUH18= M5J'E>MV:AC7+L)?ESY0==DF:PA7Z#2@%(6"0BM@Z=2*K-\*M.N@@MD*I7K8O MJ&=3G%5(%Q^L9S5J*WK-ZC+/LXZ)!ZRW!)YUIM;O[*%G];F+SN;X'SPO*=@G M"O:PDDWT9Z'.:S&17:4;O8)S;#]?O7NGVIG=E]NI]>#^WM-;:*HN[M3GG&VS M0;5W:C9X0+<9W/!PNQ.,G!<+Z]0)<'\K>)4Y.0QF?FH)>$!/&,[<;S,/6LS- ML_-H!GQ=7 0$6K(ME>4AI)ZM+QNWQ1&[,3_#-W/<,1_IRTEQ_CW!ES>;.\+7 M"14HA94*95V/E.2\O"R4 \GRXC3\Q*0Z6Q>/&W7! JX-U/L58_(XT 'J*]OT M'U!+ P04 " "=>@Q1U5L7@LH" #\!@ &0 'AL+W=O:-"A'$4]<."<1DD8[]VIY.QJJS@$N\TF*HH MF'Z>H5"[27 9'!86?)-;MQ FXY)M<(GVOKS3- L;E(P7* U7$C2N)\'T*X>7*F'\%W;[LU$ :66L M*O;&Q*#@LOZSIWT2X M=$E96DV[G.QLA)1X.+4SW/F>US_B$SS[<*FES Y]EAMEK^Y#X-R+B@XA9W KX MO9(=Z$:?(([BZ'XYA[,/YRVPW28V70_;;8_-[^G*6$WE\Z<%L]=@]CQF[P3F M-3,YE(QG0!<*6*$J2<'E,A45Q8(&8'.$@CQ7&JGXK^[QKPWNOFU*PVK7U:=[27 MX_6[<,OTADM#'-=D&G4&5 "Z[K7UQ*K2][>5LM0M_3"GYPFU.T#[:Z7L8>(< M- ]>\@]02P,$% @ G7H,4;H7],1Y @ 008 !D !X;"]W;W)K&ULA55;;YLP%/XK%MI#)ZWE$@*T(DB]J-JF=HJ:=7N8 M]N# 26(5V\PV2?OO=VPHBAJ:OH!OW\TVAWPGU9/> !CRS&NA9][&F.;"]W6Y M 4[UF6Q X,Q**DX-=M7:UXT"6CD0K_TH"!*?4R:\(G=C< M4_5R!;7QUX8.N-L0-^D3=T#0LPC\U<8<\?6"K&06@F!5&PFGF7X<55 M9M>[!;\8[/1>F]@D2RF?;.=;-?,":PAJ*(UEH/C:PC74M25"&_]Z3F^0M,#] M]BO[KYI$*5K2MS8/0]&!UP)KHW?>[W80\0A>\ HAX0.=^=D'-Y0PTM HR,D-&,IJ_3GW#?JR['[9>[CJ/$3O>/C>BC,R";Z0*(B" MQ\4-.?GTAL7'5$.T:(@6.=K)\6A_+I?:*#S]OTV+G49R&XV+306SZD5@T)C8]$(N3 M)$O'Q9)!+#DJ]E,:6I-5=\UX?\UJ=X^:_K*->4D.O(19?!Y/QLVD@YGTJ)D[ MT/J"4"Y;8;#.8&W3:(")-6&\:0U4A D#.&K&/*4'GD[#) O/QSUE@Z?LXPT: MD\L.+II5B]YN@;]7$6QQO:=JS83&/5XA,#A+T;#J"E;7,;)Q16(I#98&PO=V]R:W-H965T'+B 5?]@MDG:_WYG0VBZ)=EX@+-]WW??G;E+-TH_ MFAK DB?!I9D%M;7-91B:H@9!S;EJ0.+)2FE!+2YU%9I& RT]2/ PCJ)I*"B3 M09;ZO87.4M5:SB0L-#&M$%0_7P-7FUDP"K8;=ZRJK=L(L[2A%=R#?6@6&E?A MP%(R =(P)8F&U2RX&EWF$^?O';XQV)@=F[A,EDH]NL6GC L%D]Z5/?1UV ,BS'Q#W@/A/0'( ,.X!8Y]H MI\RG-:>69JE6&Z*=-[(YP]?&HS$;)MTMWEN-IPQQ-LN5$,SBM5AS1G(E+9,5 MR(*!(526Y NSK**^X"=SL)1Q0[Y2K:DK_BEY2_*6-] TH,F-:+AZ=DSDJM( MWOIQ"V()^B=Z+L"BUXO_SM'#_9R_3DQ^%S*! ^1+RXF!P)/AL"3_PVLP8!>[\UZ\G?6HRB9).,A M>'=]__;K1(8['25 5W[0&$R]E;9KKF%WF&57OH7#%_=N$-Y273%I"(<50J/S M"]2@N^'2+:QJ?'\NE<5N]V:-\QBT<\#SE5)VNW !A@F?_0902P,$% @ MG7H,4;(E:?;, @ /@@ !D !X;"]W;W)K&UL MK5;?;YLP$/Y7++2'5MH" ?*K2B(U2:NM4J>H4=>':0\.7()5;%/;A$[:'S_; M$)HU!&737L V]WUWG\^^8UQP\2P3 (5>:M[7M^EF#!G.K9K2S$=\UREA,%2()E3BL7/&:2\F#A= M9[_P0+:),@ON=)SA+:Q /69+H6=NS1(3"DP2SI" S<2Y[EXM1L;>&GPC4,B# M,3)*UIP_F\F7>.)X)B!((5*& >O7#N:0IH9(A_%2<3JU2P,\'._9;ZUVK66- M) \(3P#""A#:G2FEV'U88(6G8\$+)(RU9C,# MNYD6K>439M*^4D)_)1JGIJM\+>$E!Z;0S4X_);I8@,(DE>@K%@*;K%RB3^AQ MM4 7'R['KM).#=2-*@>STH%_PD$7W7.F$HEN6 QQ W[>CN^WX%TMME;L[Q7/ M_%;"ZWS;0=[@(_(]WVN*IQU^E[,."KR3\,79\.ZH14U0YR^P?.$)OJ7@$4 L MT49PB@J3,IU*> 41$0E-\DJ^ON4S16$W#?U^J*7L#E4<6_6"X,WHCUC#.M:P M-=;W9PU]OP>Z!O&C91]Z-7>OE?NI4JXXRG(1);H4H(A3JDN+OD/1<]/!+1E[ M!QJ#?CCTO!,R^W4H_;-"V2U_MS[7S;'L96\T96>]QV)+F$0I M;#2EUQGH RG*;E5.%,]L_5YSI;N!'2:ZP8,P!OK[AG.UGQ@']2_#]#=02P,$ M% @ G7H,40K?X_Y @ X H T !X;"]S='EL97,N>&ULU5;?:]LP M$/Y7A#)&"Z.VTR9EJVW8"H7!5@K-P]Z*8I]M@7YXLIPE_>LG68[MI'4)?=B2 ME^CN.]UWGZ1SI+#2&P:/!8!&:\Y$%>%"Z_*+YU5) 9Q4%[($82*95)QHXZK< MJTH%)*UL$F?>U/?G'B=4X#@4-;_CND*)K(6.\%4'(3=\3R,07OC^.+$-CI'/#R-_BWN, M^OI W6\+=_1>N_]QF$G1'\,E=H"I3SB@%6$1OB6,+A6U61GAE&TV%'+ MTK-!K24W1DI)+@5I-&PS6L/0)L#8H_UN?F4[W.ML<+*^/5?1F490:SH:YUC^ M(9OC'M+Z[^)%)5U)_:TVRQ&-;]L%'A1D=-WXZZP3,,8>C+.3LF2;KXSF@H-; M_,$%XY!L\U A%7TVU6RK) 8 A=$*E*;)$/FC2+F M=ZVTSH;USP]0UE>.PB9Z<@_F&7%\R;@OV;-OX+4$L#!!0 ( )UZ#%&7 MBKL
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
&PO=V]R:W-H965T&UL4$L! A0#% M @ G7H,409$WZR( @ .0< !D ("! 7L 'AL+W=O&PO=V]R:W-H965T! !X M;"]W;W)K&UL4$L! A0#% @ G7H,40>H)!^I M P O@T !D ("!$(4 'AL+W=O@Q1U5L7@LH" #\!@ &0 M@('PB >&PO=V]R:W-H965T0( $$& 9 " @?&+ !X;"]W;W)K&UL4$L! A0#% @ G7H,43FOV_%] @ [04 !D M ("!H8X 'AL+W=O@Q1LB5I]LP" ^" &0 @(%5D0 >&PO=V]R M:W-H965T7!E&UL4$L%!@ F "8 00H &2> $! end XML 42 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 43 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 107 233 1 false 29 0 false 5 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://provectusbio.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://provectusbio.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://provectusbio.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://provectusbio.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://provectusbio.com/role/StatementsOfComprehensiveLoss Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) Sheet http://provectusbio.com/role/StatementsOfChangesInStockholdersDeficiency Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) Statements 6 false false R7.htm 00000007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://provectusbio.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 00000008 - Disclosure - Business Organization, Nature of Operations and Basis of Presentation Sheet http://provectusbio.com/role/BusinessOrganizationNatureOfOperationsAndBasisOfPresentation Business Organization, Nature of Operations and Basis of Presentation Notes 8 false false R9.htm 00000009 - Disclosure - Liquidity and Going Concern Sheet http://provectusbio.com/role/LiquidityAndGoingConcern Liquidity and Going Concern Notes 9 false false R10.htm 00000010 - Disclosure - Critical Accounting Policies Sheet http://provectusbio.com/role/CriticalAccountingPolicies Critical Accounting Policies Notes 10 false false R11.htm 00000011 - Disclosure - Convertible Notes Payable Notes http://provectusbio.com/role/ConvertibleNotesPayable Convertible Notes Payable Notes 11 false false R12.htm 00000012 - Disclosure - Related Party Transactions Sheet http://provectusbio.com/role/RelatedPartyTransactions Related Party Transactions Notes 12 false false R13.htm 00000013 - Disclosure - Receivables Sheet http://provectusbio.com/role/Receivables Receivables Notes 13 false false R14.htm 00000014 - Disclosure - Stockholders' Deficiency Sheet http://provectusbio.com/role/StockholdersDeficiency Stockholders' Deficiency Notes 14 false false R15.htm 00000015 - Disclosure - Leases Sheet http://provectusbio.com/role/Leases Leases Notes 15 false false R16.htm 00000016 - Disclosure - Commitments, Contingencies and Litigation Sheet http://provectusbio.com/role/CommitmentsContingenciesAndLitigation Commitments, Contingencies and Litigation Notes 16 false false R17.htm 00000017 - Disclosure - Subsequent Events Sheet http://provectusbio.com/role/SubsequentEvents Subsequent Events Notes 17 false false R18.htm 00000018 - Disclosure - Critical Accounting Policies (Policies) Sheet http://provectusbio.com/role/CriticalAccountingPoliciesPolicies Critical Accounting Policies (Policies) Policies http://provectusbio.com/role/CriticalAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Receivables (Tables) Sheet http://provectusbio.com/role/ReceivablesTables Receivables (Tables) Tables http://provectusbio.com/role/Receivables 19 false false R20.htm 00000020 - Disclosure - Leases (Tables) Sheet http://provectusbio.com/role/LeasesTables Leases (Tables) Tables http://provectusbio.com/role/Leases 20 false false R21.htm 00000021 - Disclosure - Liquidity and Going Concern (Details Narrative) Sheet http://provectusbio.com/role/LiquidityAndGoingConcernDetailsNarrative Liquidity and Going Concern (Details Narrative) Details http://provectusbio.com/role/LiquidityAndGoingConcern 21 false false R22.htm 00000022 - Disclosure - Convertible Notes Payable (Details Narrative) Notes http://provectusbio.com/role/ConvertibleNotesPayableDetailsNarrative Convertible Notes Payable (Details Narrative) Details http://provectusbio.com/role/ConvertibleNotesPayable 22 false false R23.htm 00000023 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://provectusbio.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://provectusbio.com/role/RelatedPartyTransactions 23 false false R24.htm 00000024 - Disclosure - Receivables - Summary of Receivables (Details) Sheet http://provectusbio.com/role/Receivables-SummaryOfReceivablesDetails Receivables - Summary of Receivables (Details) Details 24 false false R25.htm 00000025 - Disclosure - Stockholders' Deficiency (Details Narrative) Sheet http://provectusbio.com/role/StockholdersDeficiencyDetailsNarrative Stockholders' Deficiency (Details Narrative) Details http://provectusbio.com/role/StockholdersDeficiency 25 false false R26.htm 00000026 - Disclosure - Leases (Details Narrative) Sheet http://provectusbio.com/role/LeasesDetailsNarrative Leases (Details Narrative) Details http://provectusbio.com/role/LeasesTables 26 false false R27.htm 00000027 - Disclosure - Leases - Schedule of Right-of-use Assets and Liabilities (Details) Sheet http://provectusbio.com/role/Leases-ScheduleOfRight-of-useAssetsAndLiabilitiesDetails Leases - Schedule of Right-of-use Assets and Liabilities (Details) Details 27 false false R28.htm 00000028 - Disclosure - Leases - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) Sheet http://provectusbio.com/role/Leases-ScheduleOfFutureMinimumPaymentsUnderNon-cancellableLeaseDetails Leases - Schedule of Future Minimum Payments Under Non-cancellable Lease (Details) Details 28 false false R29.htm 00000029 - Disclosure - Commitments, Contingencies and Litigation (Details Narrative) Sheet http://provectusbio.com/role/CommitmentsContingenciesAndLitigationDetailsNarrative Commitments, Contingencies and Litigation (Details Narrative) Details http://provectusbio.com/role/CommitmentsContingenciesAndLitigation 29 false false R30.htm 00000030 - Disclosure - Subsequent Events (Details Narrative) Sheet http://provectusbio.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://provectusbio.com/role/SubsequentEvents 30 false false All Reports Book All Reports pvct-20200630.xml pvct-20200630.xsd pvct-20200630_cal.xml pvct-20200630_def.xml pvct-20200630_lab.xml pvct-20200630_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 46 0001493152-20-015327-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-20-015327-xbrl.zip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�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end